HRP20221487T1 - Izoindolinonski inhibitori međudjelovanja mdm2-p53 s protuumorskom aktivnošću - Google Patents
Izoindolinonski inhibitori međudjelovanja mdm2-p53 s protuumorskom aktivnošću Download PDFInfo
- Publication number
- HRP20221487T1 HRP20221487T1 HRP20221487TT HRP20221487T HRP20221487T1 HR P20221487 T1 HRP20221487 T1 HR P20221487T1 HR P20221487T T HRP20221487T T HR P20221487TT HR P20221487 T HRP20221487 T HR P20221487T HR P20221487 T1 HRP20221487 T1 HR P20221487T1
- Authority
- HR
- Croatia
- Prior art keywords
- chlorophenyl
- dihydro
- isoindol
- methyl
- methoxy
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 7
- 230000001093 anti-cancer Effects 0.000 title 1
- 230000003993 interaction Effects 0.000 title 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 66
- 125000000623 heterocyclic group Chemical group 0.000 claims 28
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 239000012453 solvate Substances 0.000 claims 14
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 150000002825 nitriles Chemical class 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 7
- -1 haloC1-6alkyl Chemical group 0.000 claims 7
- 125000005842 heteroatom Chemical group 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 238000011321 prophylaxis Methods 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 238000011282 treatment Methods 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 229910052801 chlorine Inorganic materials 0.000 claims 5
- 239000000460 chlorine Substances 0.000 claims 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 5
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 5
- 235000019260 propionic acid Nutrition 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 238000002560 therapeutic procedure Methods 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 150000001721 carbon Chemical group 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- JDCHPEZNOKLHPK-KJEAJVGRSA-N (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxoisoindol-2-yl]-2-methylpropanoic acid Chemical compound ClC1=CC=C(C=C1)[C@H]([C@@H](C(=O)O)C)N1[C@@](C2=C(C=C(C=C2C1=O)[C@](CC)(C1CCOCC1)O)F)(OC)C1=CC=C(C=C1)Cl JDCHPEZNOKLHPK-KJEAJVGRSA-N 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- DMHHJJRAOBKLND-SZAHLOSFSA-N 2-[5-chloro-2-[[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxoisoindol-2-yl]methyl]phenyl]-2-methylpropanoic acid Chemical compound ClC=1C=CC(=C(C=1)C(C(=O)O)(C)C)CN1[C@@](C2=C(C=C(C=C2C1=O)[C@](CC)(C1CCOCC1)O)F)(OC)C1=CC=C(C=C1)Cl DMHHJJRAOBKLND-SZAHLOSFSA-N 0.000 claims 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims 2
- 210000001015 abdomen Anatomy 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 208000006178 malignant mesothelioma Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- FLAAYSHQWIAMDD-MFMCTBQISA-N (2S)-2-[(1R)-1-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-1-[[1-(hydroxymethyl)cyclopropyl]methoxy]-3-oxoisoindol-5-yl]-2-hydroxy-N-methylpropanamide Chemical compound C[C@](C1=CC2=C(C=C1)[C@@](N(C2=O)CC3=CC=C(C=C3)Cl)(C4=CC=C(C=C4)Cl)OCC5(CC5)CO)(C(=O)NC)O FLAAYSHQWIAMDD-MFMCTBQISA-N 0.000 claims 1
- OAWFYJRYUZCBKK-SSEXGKCCSA-N (3R)-2-[(4-chloro-2-methylsulfanylphenyl)methyl]-3-(4-chlorophenyl)-4-fluoro-3-[[1-(hydroxymethyl)cyclopropyl]methoxy]-6-(2-hydroxypropan-2-yl)isoindol-1-one Chemical compound ClC1=CC(=C(C=C1)CN1C(C2=CC(=CC(=C2[C@]1(OCC1(CC1)CO)C1=CC=C(C=C1)Cl)F)C(C)(C)O)=O)SC OAWFYJRYUZCBKK-SSEXGKCCSA-N 0.000 claims 1
- RXUWUIRMPWZSAR-SSEXGKCCSA-N (3R)-2-[(4-chloro-2-methylsulfonylphenyl)methyl]-3-(4-chlorophenyl)-3-[[1-(hydroxymethyl)cyclopropyl]methoxy]-6-(2-hydroxypropan-2-yl)isoindol-1-one Chemical compound CC(C)(C1=CC2=C(C=C1)[C@@](N(C2=O)CC3=C(C=C(C=C3)Cl)S(=O)(=O)C)(C4=CC=C(C=C4)Cl)OCC5(CC5)CO)O RXUWUIRMPWZSAR-SSEXGKCCSA-N 0.000 claims 1
- FATKFLNSLQQUOY-BDJZEIKTSA-N (3R)-2-[(4-chloro-2-methylsulfonylphenyl)methyl]-3-(4-chlorophenyl)-4-fluoro-3-[(1-hydroxycyclopropyl)methoxy]-6-[1-hydroxy-1-(1-methylpyrazol-4-yl)ethyl]isoindol-1-one Chemical compound ClC1=CC(=C(C=C1)CN1C(C2=CC(=CC(=C2[C@]1(OCC1(CC1)O)C1=CC=C(C=C1)Cl)F)C(C)(C=1C=NN(C=1)C)O)=O)S(=O)(=O)C FATKFLNSLQQUOY-BDJZEIKTSA-N 0.000 claims 1
- NTYHQRPYZXGTGT-SZFCLFMZSA-N (3R)-2-[(4-chloro-2-methylsulfonylphenyl)methyl]-3-(4-chlorophenyl)-4-fluoro-3-[[1-(hydroxymethyl)cyclopropyl]methoxy]-6-(2-hydroxy-1-piperazin-1-ylpropan-2-yl)isoindol-1-one Chemical compound ClC1=CC(=C(C=C1)CN1C(C2=CC(=CC(=C2[C@]1(OCC1(CC1)CO)C1=CC=C(C=C1)Cl)F)C(CN1CCNCC1)(C)O)=O)S(=O)(=O)C NTYHQRPYZXGTGT-SZFCLFMZSA-N 0.000 claims 1
- UZPANWLGEIIIFW-SSEXGKCCSA-N (3R)-2-[(4-chloro-2-methylsulfonylphenyl)methyl]-3-(4-chlorophenyl)-4-fluoro-3-[[1-(hydroxymethyl)cyclopropyl]methoxy]-6-(2-hydroxypropan-2-yl)isoindol-1-one Chemical compound ClC1=CC(=C(C=C1)CN1C(C2=CC(=CC(=C2[C@]1(OCC1(CC1)CO)C1=CC=C(C=C1)Cl)F)C(C)(C)O)=O)S(=O)(=O)C UZPANWLGEIIIFW-SSEXGKCCSA-N 0.000 claims 1
- MNUHQOFWGYDTKI-QWOOXDRHSA-N (3R)-2-[(4-chloro-2-methylsulfonylphenyl)methyl]-3-(4-chlorophenyl)-4-fluoro-3-[[1-(hydroxymethyl)cyclopropyl]methoxy]-6-[(1S)-1-hydroxy-1-(1-methylpiperidin-4-yl)ethyl]isoindol-1-one Chemical compound C[C@](C1CCN(CC1)C)(C2=CC3=C(C(=C2)F)[C@@](N(C3=O)CC4=C(C=C(C=C4)Cl)S(=O)(=O)C)(C5=CC=C(C=C5)Cl)OCC6(CC6)CO)O MNUHQOFWGYDTKI-QWOOXDRHSA-N 0.000 claims 1
- IRIZYNABKNVLML-BZKUTMRRSA-N (3R)-2-[(4-chloro-2-methylsulfonylphenyl)methyl]-3-(4-chlorophenyl)-4-fluoro-3-[[1-(hydroxymethyl)cyclopropyl]methoxy]-6-[(S)-hydroxy(oxan-4-yl)methyl]isoindol-1-one Chemical compound CS(=O)(=O)C1=C(C=CC(=C1)Cl)CN2C(=O)C3=C([C@@]2(C4=CC=C(C=C4)Cl)OCC5(CC5)CO)C(=CC(=C3)[C@H](C6CCOCC6)O)F IRIZYNABKNVLML-BZKUTMRRSA-N 0.000 claims 1
- XPPOSVDBYKUPEU-ZGVDRVBQSA-N (3R)-2-[(4-chloro-2-methylsulfonylphenyl)methyl]-3-(4-chlorophenyl)-4-fluoro-6-(2-hydroxy-1-methoxypropan-2-yl)-3-[[1-(hydroxymethyl)cyclopropyl]methoxy]isoindol-1-one Chemical compound ClC1=CC(=C(C=C1)CN1C(C2=CC(=CC(=C2[C@]1(OCC1(CC1)CO)C1=CC=C(C=C1)Cl)F)C(COC)(C)O)=O)S(=O)(=O)C XPPOSVDBYKUPEU-ZGVDRVBQSA-N 0.000 claims 1
- YMXGZYIWCPLVGI-NLIBRCFJSA-N (3R)-2-[(4-chloro-2-methylsulfonylphenyl)methyl]-3-(4-chlorophenyl)-4-fluoro-6-[1-(4-fluoropiperidin-4-yl)-1-hydroxypropyl]-3-methoxyisoindol-1-one Chemical compound ClC1=CC(=C(C=C1)CN1C(C2=CC(=CC(=C2[C@]1(OC)C1=CC=C(C=C1)Cl)F)C(CC)(O)C1(CCNCC1)F)=O)S(=O)(=O)C YMXGZYIWCPLVGI-NLIBRCFJSA-N 0.000 claims 1
- GEZPZMXREXHEJZ-GKHSUDMDSA-N (3R)-2-[(4-chloro-2-methylsulfonylphenyl)methyl]-3-(4-chlorophenyl)-4-fluoro-6-[2-hydroxy-1-(4-methylpiperazin-1-yl)propan-2-yl]-3-[(3R)-oxolan-3-yl]oxyisoindol-1-one Chemical compound ClC1=CC(=C(C=C1)CN1C(C2=CC(=CC(=C2[C@]1(O[C@H]1COCC1)C1=CC=C(C=C1)Cl)F)C(CN1CCN(CC1)C)(C)O)=O)S(=O)(=O)C GEZPZMXREXHEJZ-GKHSUDMDSA-N 0.000 claims 1
- GEZPZMXREXHEJZ-FNHRJEOVSA-N (3R)-2-[(4-chloro-2-methylsulfonylphenyl)methyl]-3-(4-chlorophenyl)-4-fluoro-6-[2-hydroxy-1-(4-methylpiperazin-1-yl)propan-2-yl]-3-[(3S)-oxolan-3-yl]oxyisoindol-1-one Chemical compound ClC1=CC(=C(C=C1)CN1C(C2=CC(=CC(=C2[C@]1(O[C@@H]1COCC1)C1=CC=C(C=C1)Cl)F)C(CN1CCN(CC1)C)(C)O)=O)S(=O)(=O)C GEZPZMXREXHEJZ-FNHRJEOVSA-N 0.000 claims 1
- HJVLHGXGDKFDKJ-PQHLKRTFSA-N (3R)-2-[(4-chloro-2-methylsulfonylphenyl)methyl]-3-(4-chlorophenyl)-6-[(2S)-1,2-dihydroxypropan-2-yl]-4-fluoro-3-[[1-(hydroxymethyl)cyclopropyl]methoxy]isoindol-1-one Chemical compound C[C@@](CO)(C1=CC2=C(C(=C1)F)[C@@](N(C2=O)CC3=C(C=C(C=C3)Cl)S(=O)(=O)C)(C4=CC=C(C=C4)Cl)OCC5(CC5)CO)O HJVLHGXGDKFDKJ-PQHLKRTFSA-N 0.000 claims 1
- JFAQMYZAZWRRKT-MGBGTMOVSA-N (3R)-2-[(4-chloro-2-morpholin-4-ylsulfonylphenyl)methyl]-3-(4-chlorophenyl)-3-[[1-(hydroxymethyl)cyclopropyl]methoxy]-6-(2-hydroxypropan-2-yl)isoindol-1-one Chemical compound ClC1=CC(=C(C=C1)CN1C(C2=CC(=CC=C2[C@]1(OCC1(CC1)CO)C1=CC=C(C=C1)Cl)C(C)(C)O)=O)S(=O)(=O)N1CCOCC1 JFAQMYZAZWRRKT-MGBGTMOVSA-N 0.000 claims 1
- PVRYETGYPNIACM-FRRBMJAGSA-N (3R)-2-[[4-chloro-2-[(S)-methylsulfinyl]phenyl]methyl]-3-(4-chlorophenyl)-4-fluoro-3-[[1-(hydroxymethyl)cyclopropyl]methoxy]-6-(2-hydroxypropan-2-yl)isoindol-1-one Chemical compound CC(C)(C1=CC2=C(C(=C1)F)[C@@](N(C2=O)CC3=C(C=C(C=C3)Cl)[S@@](=O)C)(C4=CC=C(C=C4)Cl)OCC5(CC5)CO)O PVRYETGYPNIACM-FRRBMJAGSA-N 0.000 claims 1
- UUZINBSIYDKSFT-PDIMESBLSA-N (3R)-3-(4-chlorophenyl)-2-[(1S)-1-(4-chlorophenyl)ethyl]-3-(2,3-dihydroxy-2-methylpropoxy)-6-(2-hydroxypropan-2-yl)isoindol-1-one Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC=C12)C(C)(C)O)=O)[C@@H](C)C1=CC=C(C=C1)Cl)OCC(CO)(C)O UUZINBSIYDKSFT-PDIMESBLSA-N 0.000 claims 1
- JLJRDOGQKDSPHW-OPLXESSESA-N (3R)-3-(4-chlorophenyl)-2-[(1S)-1-(4-chlorophenyl)ethyl]-3-[(3R,4S)-4-hydroxyoxolan-3-yl]oxy-6-(2-hydroxypropan-2-yl)isoindol-1-one Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC=C12)C(C)(C)O)=O)[C@@H](C)C1=CC=C(C=C1)Cl)O[C@@H]1COC[C@@H]1O JLJRDOGQKDSPHW-OPLXESSESA-N 0.000 claims 1
- JLJRDOGQKDSPHW-QOSCSMRQSA-N (3R)-3-(4-chlorophenyl)-2-[(1S)-1-(4-chlorophenyl)ethyl]-3-[(3S,4R)-4-hydroxyoxolan-3-yl]oxy-6-(2-hydroxypropan-2-yl)isoindol-1-one Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC=C12)C(C)(C)O)=O)[C@@H](C)C1=CC=C(C=C1)Cl)O[C@H]1COC[C@H]1O JLJRDOGQKDSPHW-QOSCSMRQSA-N 0.000 claims 1
- OBIKGGOHRXESCS-WWOZWPLTSA-N (3R)-3-(4-chlorophenyl)-2-[(1S)-1-(4-chlorophenyl)ethyl]-3-[[1-(hydroxymethyl)cyclopropyl]methoxy]-6-(2-hydroxypropan-2-yl)isoindol-1-one Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC=C12)C(C)(C)O)=O)[C@@H](C)C1=CC=C(C=C1)Cl)OCC1(CC1)CO OBIKGGOHRXESCS-WWOZWPLTSA-N 0.000 claims 1
- HLYNUXSLMMUNHC-WDWHWGHSSA-N (3R)-3-(4-chlorophenyl)-2-[(1S)-1-(4-chlorophenyl)ethyl]-6-(1,2-dihydroxypropan-2-yl)-3-[[1-(hydroxymethyl)cyclopropyl]methoxy]isoindol-1-one Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC=C12)C(CO)(C)O)=O)[C@@H](C)C1=CC=C(C=C1)Cl)OCC1(CC1)CO HLYNUXSLMMUNHC-WDWHWGHSSA-N 0.000 claims 1
- UIFBZUZURMPJLE-CRIGUBNMSA-N (3R)-3-(4-chlorophenyl)-2-[(1S)-1-(4-chlorophenyl)ethyl]-6-[(2R)-2-hydroxy-1-methoxypropan-2-yl]-3-[[1-(hydroxymethyl)cyclopropyl]methoxy]isoindol-1-one Chemical compound C[C@@H](C1=CC=C(C=C1)Cl)N2C(=O)C3=C([C@@]2(C4=CC=C(C=C4)Cl)OCC5(CC5)CO)C=CC(=C3)[C@](C)(COC)O UIFBZUZURMPJLE-CRIGUBNMSA-N 0.000 claims 1
- DKLIPENWHNVPEY-HHHXNRCGSA-N (3R)-3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-3-(2,2-difluoro-3-hydroxypropoxy)-6-(2-hydroxypropan-2-yl)isoindol-1-one Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC=C12)C(C)(C)O)=O)CC1=CC=C(C=C1)Cl)OCC(CO)(F)F DKLIPENWHNVPEY-HHHXNRCGSA-N 0.000 claims 1
- BDOTXISZENQYGP-AREMUKBSSA-N (3R)-3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-3-(2-hydroxyethoxy)-6-(2-hydroxypropan-2-yl)isoindol-1-one Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC=C12)C(C)(C)O)=O)CC1=CC=C(C=C1)Cl)OCCO BDOTXISZENQYGP-AREMUKBSSA-N 0.000 claims 1
- QFAIKCYCAGIEDP-GDLZYMKVSA-N (3R)-3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-3-(3-hydroxy-3-methylbutoxy)-6-(2-hydroxypropan-2-yl)isoindol-1-one Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC=C12)C(C)(C)O)=O)CC1=CC=C(C=C1)Cl)OCCC(C)(C)O QFAIKCYCAGIEDP-GDLZYMKVSA-N 0.000 claims 1
- RCIVCEHJWTYZDO-MUUNZHRXSA-N (3R)-3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-3-[(1-hydroxycyclopropyl)methoxy]-6-(2-hydroxypropan-2-yl)isoindol-1-one Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC=C12)C(C)(C)O)=O)CC1=CC=C(C=C1)Cl)OCC1(CC1)O RCIVCEHJWTYZDO-MUUNZHRXSA-N 0.000 claims 1
- OYVZDYIWPZZTME-SSEXGKCCSA-N (3R)-3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-3-[[1-(hydroxymethyl)cyclobutyl]methoxy]-6-(2-hydroxypropan-2-yl)isoindol-1-one Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC=C12)C(C)(C)O)=O)CC1=CC=C(C=C1)Cl)OCC1(CCC1)CO OYVZDYIWPZZTME-SSEXGKCCSA-N 0.000 claims 1
- AVCINXLMIYQZIG-NFCCVXSLSA-N (3R)-3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-3-[[1-(hydroxymethyl)cyclopropyl]methoxy]-6-(2-hydroxy-1-oxo-1-pyrrolidin-1-ylpropan-2-yl)isoindol-1-one Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC=C12)C(C(N1CCCC1)=O)(C)O)=O)CC1=CC=C(C=C1)Cl)OCC1(CC1)CO AVCINXLMIYQZIG-NFCCVXSLSA-N 0.000 claims 1
- KWVOGOFTJBHEAY-GDLZYMKVSA-N (3R)-3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-3-[[1-(hydroxymethyl)cyclopropyl]methoxy]-6-(2-hydroxypropan-2-yl)isoindol-1-one Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC=C12)C(C)(C)O)=O)CC1=CC=C(C=C1)Cl)OCC1(CC1)CO KWVOGOFTJBHEAY-GDLZYMKVSA-N 0.000 claims 1
- YJPCYIKTKXDGAX-MWZSVNGBSA-N (3R)-3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-3-[[2-(hydroxymethyl)cyclobutyl]methoxy]-6-(2-hydroxypropan-2-yl)isoindol-1-one Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC=C12)C(C)(C)O)=O)CC1=CC=C(C=C1)Cl)OCC1C(CC1)CO YJPCYIKTKXDGAX-MWZSVNGBSA-N 0.000 claims 1
- GDUHFOYTYPKEOT-GDLZYMKVSA-N (3R)-3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-3-[[3-(hydroxymethyl)oxetan-3-yl]methoxy]-6-(2-hydroxypropan-2-yl)isoindol-1-one Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC=C12)C(C)(C)O)=O)CC1=CC=C(C=C1)Cl)OCC1(COC1)CO GDUHFOYTYPKEOT-GDLZYMKVSA-N 0.000 claims 1
- QUBUREFIXVDKEB-GDLZYMKVSA-N (3R)-3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-4-fluoro-3-[[1-(hydroxymethyl)cyclopropyl]methoxy]-6-(2-hydroxypropan-2-yl)isoindol-1-one Chemical compound ClC1=CC=C(CN2C(C3=CC(=CC(=C3[C@]2(OCC2(CC2)CO)C2=CC=C(C=C2)Cl)F)C(C)(C)O)=O)C=C1 QUBUREFIXVDKEB-GDLZYMKVSA-N 0.000 claims 1
- COYLYTVXALVFKT-MUUNZHRXSA-N (3R)-3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-6-(2-hydroxypropan-2-yl)-3-(1H-pyrazol-4-ylmethoxy)isoindol-1-one Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC=C12)C(C)(C)O)=O)CC1=CC=C(C=C1)Cl)OCC=1C=NNC=1 COYLYTVXALVFKT-MUUNZHRXSA-N 0.000 claims 1
- OAZOTQYKBROZDC-HHHXNRCGSA-N (3R)-3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-6-(2-hydroxypropan-2-yl)-3-(3-hydroxypropoxy)isoindol-1-one Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC=C12)C(C)(C)O)=O)CC1=CC=C(C=C1)Cl)OCCCO OAZOTQYKBROZDC-HHHXNRCGSA-N 0.000 claims 1
- JPJMGSQFTCZFQV-GDLZYMKVSA-N (3R)-3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-6-(2-hydroxypropan-2-yl)-3-[(3-methyloxetan-3-yl)methoxy]isoindol-1-one Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC=C12)C(C)(C)O)=O)CC1=CC=C(C=C1)Cl)OCC1(COC1)C JPJMGSQFTCZFQV-GDLZYMKVSA-N 0.000 claims 1
- ITVICYXWRBVNRA-QDPGVEIFSA-N (3R)-3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-6-(2-hydroxypropan-2-yl)-3-[(3R)-oxolan-3-yl]oxyisoindol-1-one Chemical compound CC(C)(C1=CC2=C(C=C1)[C@@](N(C2=O)CC3=CC=C(C=C3)Cl)(C4=CC=C(C=C4)Cl)O[C@@H]5CCOC5)O ITVICYXWRBVNRA-QDPGVEIFSA-N 0.000 claims 1
- OTIYWWDOPCSJHZ-AFJIDDCJSA-N (3R)-3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-6-(2-hydroxypropan-2-yl)-3-[[(3S)-oxolan-3-yl]methoxy]isoindol-1-one Chemical compound CC(C)(C1=CC2=C(C=C1)[C@@](N(C2=O)CC3=CC=C(C=C3)Cl)(C4=CC=C(C=C4)Cl)OC[C@H]5CCOC5)O OTIYWWDOPCSJHZ-AFJIDDCJSA-N 0.000 claims 1
- RARQEPSEJKMFPX-SSEXGKCCSA-N (3R)-3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-6-(2-hydroxypropan-2-yl)-3-[[1-(methoxymethyl)cyclopropyl]methoxy]isoindol-1-one Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC=C12)C(C)(C)O)=O)CC1=CC=C(C=C1)Cl)OCC1(CC1)COC RARQEPSEJKMFPX-SSEXGKCCSA-N 0.000 claims 1
- NVLQHQFGNPTQCC-LMSSTIIKSA-N (3R)-3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-6-[(2R)-1,2-dihydroxypropan-2-yl]-3-[[1-(hydroxymethyl)cyclopropyl]methoxy]isoindol-1-one Chemical compound C[C@](CO)(C1=CC2=C(C=C1)[C@@](N(C2=O)CC3=CC=C(C=C3)Cl)(C4=CC=C(C=C4)Cl)OCC5(CC5)CO)O NVLQHQFGNPTQCC-LMSSTIIKSA-N 0.000 claims 1
- FLSKRFKVCWLISS-IGYGKHONSA-N (3R)-3-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-6-[(2R)-1-(dimethylamino)-2-hydroxypropan-2-yl]-3-[[1-(hydroxymethyl)cyclopropyl]methoxy]isoindol-1-one Chemical compound C[C@](CN(C)C)(C1=CC2=C(C=C1)[C@@](N(C2=O)CC3=CC=C(C=C3)Cl)(C4=CC=C(C=C4)Cl)OCC5(CC5)CO)O FLSKRFKVCWLISS-IGYGKHONSA-N 0.000 claims 1
- LTEBUYNLVXWZOS-WJOKGBTCSA-N (3R)-3-(4-chlorophenyl)-2-[(4-ethynylphenyl)methyl]-3-[[1-(hydroxymethyl)cyclopropyl]methoxy]-6-(2-hydroxypropan-2-yl)isoindol-1-one Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC=C12)C(C)(C)O)=O)CC1=CC=C(C=C1)C#C)OCC1(CC1)CO LTEBUYNLVXWZOS-WJOKGBTCSA-N 0.000 claims 1
- NBPAQCMFLGCFBK-WJOKGBTCSA-N (3R)-3-(4-chlorophenyl)-2-[(4-ethynylphenyl)methyl]-4-fluoro-3-[[1-(hydroxymethyl)cyclopropyl]methoxy]-6-(2-hydroxypropan-2-yl)isoindol-1-one Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC(=C12)F)C(C)(C)O)=O)CC1=CC=C(C=C1)C#C)OCC1(CC1)CO NBPAQCMFLGCFBK-WJOKGBTCSA-N 0.000 claims 1
- LDOCNQIRVXHZQU-IGYGKHONSA-N (3R)-3-(4-chlorophenyl)-6-[(2R)-1,2-dihydroxypropan-2-yl]-2-[(4-ethynylphenyl)methyl]-4-fluoro-3-[[1-(hydroxymethyl)cyclopropyl]methoxy]isoindol-1-one Chemical compound C[C@](CO)(C1=CC2=C(C(=C1)F)[C@@](N(C2=O)CC3=CC=C(C=C3)C#C)(C4=CC=C(C=C4)Cl)OCC5(CC5)CO)O LDOCNQIRVXHZQU-IGYGKHONSA-N 0.000 claims 1
- JMXJOWWAIDYRLU-SKTNCWGXSA-N (3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-1-ethoxy-7-fluoro-5-[(1R)-1-(4-fluorooxan-4-yl)-1-hydroxypropyl]-3-oxoisoindol-2-yl]propanoic acid Chemical compound ClC1=CC=C(C=C1)[C@H](CC(=O)O)N1[C@@](C2=C(C=C(C=C2C1=O)[C@@](CC)(O)C1(CCOCC1)F)F)(OCC)C1=CC=C(C=C1)Cl JMXJOWWAIDYRLU-SKTNCWGXSA-N 0.000 claims 1
- BVCCIEZECAVANS-AWJLRTIGSA-N (3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-5-[(1R)-1-cyclobutyl-1-hydroxyethyl]-7-fluoro-1-methoxy-3-oxoisoindol-2-yl]propanoic acid Chemical compound C[C@@](C1CCC1)(C2=CC3=C(C(=C2)F)[C@@](N(C3=O)[C@@H](CC(=O)O)C4=CC=C(C=C4)Cl)(C5=CC=C(C=C5)Cl)OC)O BVCCIEZECAVANS-AWJLRTIGSA-N 0.000 claims 1
- NAMQEWAUDBCILZ-SBYPTKLRSA-N (3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-1-[(3-fluorooxetan-3-yl)methoxy]-5-(2-hydroxybutan-2-yl)-3-oxoisoindol-2-yl]propanoic acid Chemical compound ClC1=CC=C(C=C1)[C@H](CC(=O)O)N1[C@@](C2=C(C=C(C=C2C1=O)C(C)(CC)O)F)(OCC1(COC1)F)C1=CC=C(C=C1)Cl NAMQEWAUDBCILZ-SBYPTKLRSA-N 0.000 claims 1
- PMXGSEVMEXTCLI-SGOMLOLCSA-N (3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-(2-hydroxypropan-2-yl)-3-oxo-1-[(3S)-oxolan-3-yl]oxyisoindol-2-yl]propanoic acid Chemical compound ClC1=CC=C(C=C1)[C@H](CC(=O)O)N1[C@@](C2=C(C=C(C=C2C1=O)C(C)(C)O)F)(O[C@@H]1COCC1)C1=CC=C(C=C1)Cl PMXGSEVMEXTCLI-SGOMLOLCSA-N 0.000 claims 1
- HXHSKGLWTNIZIS-WBJHVRQISA-N (3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1R)-1-(4-fluorooxan-4-yl)-1-hydroxypropyl]-3-oxo-1-(trideuteriomethoxy)isoindol-2-yl]propanoic acid Chemical compound ClC1=CC=C(C=C1)[C@H](CC(=O)O)N1[C@@](C2=C(C=C(C=C2C1=O)[C@@](CC)(O)C1(CCOCC1)F)F)(OC([2H])([2H])[2H])C1=CC=C(C=C1)Cl HXHSKGLWTNIZIS-WBJHVRQISA-N 0.000 claims 1
- KHSRSNYUTBONQS-OODHRNECSA-N (3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1R)-1-hydroxy-1-pyridin-2-ylpropyl]-1-methoxy-3-oxoisoindol-2-yl]propanoic acid Chemical compound CC[C@](C1=CC=CC=N1)(C2=CC3=C(C(=C2)F)[C@@](N(C3=O)[C@@H](CC(=O)O)C4=CC=C(C=C4)Cl)(C5=CC=C(C=C5)Cl)OC)O KHSRSNYUTBONQS-OODHRNECSA-N 0.000 claims 1
- AVDHVIXZENQIRS-HOSFBAFGSA-N (3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)ethyl]-1-methoxy-3-oxoisoindol-2-yl]propanoic acid Chemical compound C[C@](C1CCOCC1)(C2=CC3=C(C(=C2)F)[C@@](N(C3=O)[C@@H](CC(=O)O)C4=CC=C(C=C4)Cl)(C5=CC=C(C=C5)Cl)OC)O AVDHVIXZENQIRS-HOSFBAFGSA-N 0.000 claims 1
- UASWWYBCWGDNKX-BECFNDGMSA-N (3S)-3-(4-chlorophenyl)-3-[1-(4-chlorophenyl)-7-fluoro-5-[1-(4-fluoro-1-methylpiperidin-4-yl)-1-hydroxypropyl]-1-methoxy-3-oxoisoindol-2-yl]propanoic acid Chemical compound CCC(O)(C1=CC(F)=C2C(=C1)C(=O)N([C@@H](CC(O)=O)C1=CC=C(Cl)C=C1)C2(OC)C1=CC=C(Cl)C=C1)C1(F)CCN(C)CC1 UASWWYBCWGDNKX-BECFNDGMSA-N 0.000 claims 1
- KQTPBMJSGVVRKO-SKTNCWGXSA-N (4S)-4-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1R)-1-(4-fluorooxan-4-yl)-1-hydroxypropyl]-1-methoxy-3-oxoisoindol-2-yl]butanoic acid Chemical compound ClC1=CC=C(C=C1)[C@H](CCC(=O)O)N1[C@@](C2=C(C=C(C=C2C1=O)[C@@](CC)(O)C1(CCOCC1)F)F)(OC)C1=CC=C(C=C1)Cl KQTPBMJSGVVRKO-SKTNCWGXSA-N 0.000 claims 1
- ACCSRYKZIIOHIZ-LTZUXFEUSA-N (4S)-4-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[1-hydroxy-1-(1-methylpyrazol-3-yl)propyl]-1-methoxy-3-oxoisoindol-2-yl]butanoic acid Chemical compound ClC1=CC=C(C=C1)[C@H](CCC(=O)O)N1[C@@](C2=C(C=C(C=C2C1=O)C(CC)(C1=NN(C=C1)C)O)F)(OC)C1=CC=C(C=C1)Cl ACCSRYKZIIOHIZ-LTZUXFEUSA-N 0.000 claims 1
- NOKLTVPSPDXSBE-HUTUBIKLSA-N (4S)-4-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1R)-1-(4-fluorooxan-4-yl)-1-hydroxypropyl]-1-methoxy-3-oxoisoindol-2-yl]-4-(4-methoxyphenyl)butanoic acid Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC(=C12)F)[C@@](CC)(O)C1(CCOCC1)F)=O)[C@@H](CCC(=O)O)C1=CC=C(C=C1)OC)OC NOKLTVPSPDXSBE-HUTUBIKLSA-N 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims 1
- CHHGWWCMCGHFMJ-GDLZYMKVSA-N 1-[[(1R)-1-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-5-(2-hydroxypropan-2-yl)-3-oxoisoindol-1-yl]oxymethyl]cyclopropane-1-carbonitrile Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC=C12)C(C)(C)O)=O)CC1=CC=C(C=C1)Cl)OCC1(CC1)C#N CHHGWWCMCGHFMJ-GDLZYMKVSA-N 0.000 claims 1
- IAJLMKLNFWIPMA-GDLZYMKVSA-N 1-[[(1R)-1-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-5-(2-hydroxypropan-2-yl)-3-oxoisoindol-1-yl]oxymethyl]cyclopropane-1-carboxylic acid Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC=C12)C(C)(C)O)=O)CC1=CC=C(C=C1)Cl)OCC1(CC1)C(=O)O IAJLMKLNFWIPMA-GDLZYMKVSA-N 0.000 claims 1
- QXTIAAQSOXPAAN-SSEXGKCCSA-N 1-[[(1R)-2-[(4-chloro-2-methylsulfonylphenyl)methyl]-1-(4-chlorophenyl)-7-fluoro-5-(2-hydroxypropan-2-yl)-3-oxoisoindol-1-yl]oxymethyl]cyclopropane-1-carboxamide Chemical compound ClC1=CC(=C(C=C1)CN1[C@](C2=C(C=C(C=C2C1=O)C(C)(C)O)F)(C1=CC=C(C=C1)Cl)OCC1(CC1)C(=O)N)S(=O)(=O)C QXTIAAQSOXPAAN-SSEXGKCCSA-N 0.000 claims 1
- YLXVSCUQMYZKFT-CQTOTRCISA-N 1-[[(1R)-2-[(4-chloro-2-methylsulfonylphenyl)methyl]-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(1-methylpyrazol-4-yl)ethyl]-3-oxoisoindol-1-yl]oxymethyl]cyclopropane-1-carboxamide Chemical compound C[C@](C1=CC2=C(C(=C1)F)[C@@](N(C2=O)CC3=C(C=C(C=C3)Cl)S(=O)(=O)C)(C4=CC=C(C=C4)Cl)OCC5(CC5)C(=O)N)(C6=CN(N=C6)C)O YLXVSCUQMYZKFT-CQTOTRCISA-N 0.000 claims 1
- WPEIHYLRRFWOGP-SZFCLFMZSA-N 1-[[(1R)-2-[(4-chloro-2-methylsulfonylphenyl)methyl]-1-(4-chlorophenyl)-7-fluoro-5-[1-hydroxy-1-(oxan-4-yl)ethyl]-3-oxoisoindol-1-yl]oxymethyl]cyclopropane-1-carboxamide Chemical compound ClC1=CC(=C(C=C1)CN1[C@](C2=C(C=C(C=C2C1=O)C(C)(C1CCOCC1)O)F)(C1=CC=C(C=C1)Cl)OCC1(CC1)C(=O)N)S(=O)(=O)C WPEIHYLRRFWOGP-SZFCLFMZSA-N 0.000 claims 1
- FZOWPLQXTSEWMX-SSEXGKCCSA-N 1-[[(1R)-2-[[4-chloro-2-(hydroxymethyl)phenyl]methyl]-1-(4-chlorophenyl)-7-fluoro-5-(2-hydroxypropan-2-yl)-3-oxoisoindol-1-yl]oxymethyl]cyclopropane-1-carbonitrile Chemical compound ClC1=CC(=C(C=C1)CN1[C@](C2=C(C=C(C=C2C1=O)C(C)(C)O)F)(C1=CC=C(C=C1)Cl)OCC1(CC1)C#N)CO FZOWPLQXTSEWMX-SSEXGKCCSA-N 0.000 claims 1
- QSQWTXWPCPYZCQ-ZGVDRVBQSA-N 2-[(1R)-1-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-1-[[1-(hydroxymethyl)cyclopropyl]methoxy]-3-oxoisoindol-5-yl]-2-hydroxy-N,N-dimethylpropanamide Chemical compound ClC1=CC=C(CN2[C@@](C3=CC=C(C=C3C2=O)C(C(=O)N(C)C)(C)O)(OCC2(CC2)CO)C2=CC=C(C=C2)Cl)C=C1 QSQWTXWPCPYZCQ-ZGVDRVBQSA-N 0.000 claims 1
- RRQCJUUJERJVBP-MUUNZHRXSA-N 2-[(1R)-1-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-5-(2-hydroxypropan-2-yl)-3-oxoisoindol-1-yl]oxy-N,N-dimethylacetamide Chemical compound ClC1=CC=C(CN2[C@](C3=CC=C(C=C3C2=O)C(C)(C)O)(C2=CC=C(C=C2)Cl)OCC(=O)N(C)C)C=C1 RRQCJUUJERJVBP-MUUNZHRXSA-N 0.000 claims 1
- MFPOPVHVIGVWNK-ROJLCIKYSA-N 2-[4-[(1R)-1-[(1R)-1-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-7-fluoro-1-methoxy-3-oxoisoindol-5-yl]-1-hydroxypropyl]piperidin-1-yl]acetic acid Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC(=C12)F)[C@](CC)(O)C1CCN(CC1)CC(=O)O)=O)CC1=CC=C(C=C1)Cl)OC MFPOPVHVIGVWNK-ROJLCIKYSA-N 0.000 claims 1
- MFPOPVHVIGVWNK-AJQTZOPKSA-N 2-[4-[(1S)-1-[(1R)-1-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-7-fluoro-1-methoxy-3-oxoisoindol-5-yl]-1-hydroxypropyl]piperidin-1-yl]acetic acid Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC(=C12)F)[C@@](CC)(O)C1CCN(CC1)CC(=O)O)=O)CC1=CC=C(C=C1)Cl)OC MFPOPVHVIGVWNK-AJQTZOPKSA-N 0.000 claims 1
- KSQHEVCOEVTEOI-ROJLCIKYSA-N 2-[5-chloro-2-[[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1R)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxoisoindol-2-yl]methyl]phenyl]acetic acid Chemical compound ClC=1C=CC(=C(C=1)CC(=O)O)CN1[C@@](C2=C(C=C(C=C2C1=O)[C@@](CC)(C1CCOCC1)O)F)(OC)C1=CC=C(C=C1)Cl KSQHEVCOEVTEOI-ROJLCIKYSA-N 0.000 claims 1
- KSQHEVCOEVTEOI-AJQTZOPKSA-N 2-[5-chloro-2-[[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxoisoindol-2-yl]methyl]phenyl]acetic acid Chemical compound ClC=1C=CC(=C(C=1)CC(=O)O)CN1[C@@](C2=C(C=C(C=C2C1=O)[C@](CC)(C1CCOCC1)O)F)(OC)C1=CC=C(C=C1)Cl KSQHEVCOEVTEOI-AJQTZOPKSA-N 0.000 claims 1
- JJZSDEJWGNDCRG-XGDNGBMYSA-N 2-[5-chloro-2-[[1-(4-chlorophenyl)-7-fluoro-5-[(1R)-1-(4-fluorooxan-4-yl)-1-hydroxypropyl]-1-methoxy-3-oxoisoindol-2-yl]methyl]phenoxy]acetic acid Chemical compound ClC=1C=CC(=C(OCC(=O)O)C=1)CN1C(C2=C(C=C(C=C2C1=O)[C@@](CC)(O)C1(CCOCC1)F)F)(OC)C1=CC=C(C=C1)Cl JJZSDEJWGNDCRG-XGDNGBMYSA-N 0.000 claims 1
- AMRXPNINJISJEN-ROJLCIKYSA-N 2-[[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1R)-1-(4-fluorooxan-4-yl)-1-hydroxypropyl]-1-methoxy-3-oxoisoindol-2-yl]methyl]-5-methoxybenzoic acid Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC(=C12)F)[C@@](CC)(O)C1(CCOCC1)F)=O)CC1=C(C(=O)O)C=C(C=C1)OC)OC AMRXPNINJISJEN-ROJLCIKYSA-N 0.000 claims 1
- XFQWQHWLXCPJND-ROJLCIKYSA-N 2-[[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1R)-1-(4-fluorooxan-4-yl)-1-hydroxypropyl]-1-methoxy-3-oxoisoindol-2-yl]methyl]-5-methylbenzoic acid Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC(=C12)F)[C@@](CC)(O)C1(CCOCC1)F)=O)CC1=C(C(=O)O)C=C(C=C1)C)OC XFQWQHWLXCPJND-ROJLCIKYSA-N 0.000 claims 1
- ZKUGFHUACFYRES-JHOUSYSJSA-N 3-[4-[(1S)-1-[(1R)-1-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-7-fluoro-1-methoxy-3-oxoisoindol-5-yl]-1-hydroxypropyl]piperidin-1-yl]propanoic acid Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC(=C12)F)[C@@](CC)(O)C1CCN(CC1)CCC(=O)O)=O)CC1=CC=C(C=C1)Cl)OC ZKUGFHUACFYRES-JHOUSYSJSA-N 0.000 claims 1
- DLDOXTZEZBHSKM-PRLHHBRKSA-N 4-[(1R)-1-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(1-methylimidazol-4-yl)propyl]-3-oxo-1-[(3S)-oxolan-3-yl]oxyisoindol-2-yl]-2-hydroxyethyl]benzonitrile Chemical compound CC[C@](C1=CC2=C(C(=C1)F)[C@@](N(C2=O)[C@@H](CO)C3=CC=C(C=C3)C#N)(C4=CC=C(C=C4)Cl)O[C@H]5CCOC5)(C6=CN(C=N6)C)O DLDOXTZEZBHSKM-PRLHHBRKSA-N 0.000 claims 1
- KUYDFZZMIJDWQY-SSEXGKCCSA-N 4-[[(1R)-1-(4-chlorophenyl)-1-[[1-(hydroxymethyl)cyclopropyl]methoxy]-5-(2-hydroxypropan-2-yl)-3-oxoisoindol-2-yl]methyl]benzonitrile Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC=C12)C(C)(C)O)=O)CC1=CC=C(C#N)C=C1)OCC1(CC1)CO KUYDFZZMIJDWQY-SSEXGKCCSA-N 0.000 claims 1
- ZOWAIYZZMIRJLG-SZAHLOSFSA-N 4-[[(1R)-1-(4-chlorophenyl)-7-fluoro-1-[[1-(hydroxymethyl)cyclopropyl]methoxy]-5-[(1S)-1-hydroxy-1-(1-methylimidazol-4-yl)propyl]-3-oxoisoindol-2-yl]methyl]benzonitrile Chemical compound CC[C@](C1=CC2=C(C(=C1)F)[C@@](N(C2=O)CC3=CC=C(C=C3)C#N)(C4=CC=C(C=C4)Cl)OCC5(CC5)CO)(C6=CN(C=N6)C)O ZOWAIYZZMIRJLG-SZAHLOSFSA-N 0.000 claims 1
- ZOWAIYZZMIRJLG-MUADHRSZSA-N 4-[[(1R)-1-(4-chlorophenyl)-7-fluoro-1-[[1-(hydroxymethyl)cyclopropyl]methoxy]-5-[1-hydroxy-1-(1-methylimidazol-4-yl)propyl]-3-oxoisoindol-2-yl]methyl]benzonitrile Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC(=C12)F)C(CC)(C=1N=CN(C=1)C)O)=O)CC1=CC=C(C#N)C=C1)OCC1(CC1)CO ZOWAIYZZMIRJLG-MUADHRSZSA-N 0.000 claims 1
- LQLKHTDURGSYEY-FNHRJEOVSA-N 4-[[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[1-hydroxy-1-(1-methylimidazol-4-yl)propyl]-3-oxo-1-[(3S)-oxolan-3-yl]oxyisoindol-2-yl]methyl]-3-(hydroxymethyl)benzonitrile Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC(=C12)F)C(CC)(C=1N=CN(C=1)C)O)=O)CC1=C(C=C(C#N)C=C1)CO)O[C@@H]1COCC1 LQLKHTDURGSYEY-FNHRJEOVSA-N 0.000 claims 1
- CDUKUNZREUVQKN-UBORAUAPSA-N 4-[[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[1-hydroxy-1-(1-methylimidazol-4-yl)propyl]-3-oxo-1-[(3S)-oxolan-3-yl]oxyisoindol-2-yl]methyl]benzonitrile Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC(=C12)F)C(CC)(C=1N=CN(C=1)C)O)=O)CC1=CC=C(C#N)C=C1)O[C@@H]1COCC1 CDUKUNZREUVQKN-UBORAUAPSA-N 0.000 claims 1
- RGPOYMGRXRWDFL-BJKOFHAPSA-N 4-[[(1R)-5-[(2R)-1,2-dihydroxypropan-2-yl]-1-[[1-(hydroxymethyl)cyclopropyl]methoxy]-1-methyl-3-oxoisoindol-2-yl]methyl]benzonitrile Chemical compound C[C@]1(C2=C(C=C(C=C2)[C@](C)(CO)O)C(=O)N1CC3=CC=C(C=C3)C#N)OCC4(CC4)CO RGPOYMGRXRWDFL-BJKOFHAPSA-N 0.000 claims 1
- DEAVUDZEMMDBRA-SSEXGKCCSA-N 5-chloro-2-[[(1R)-1-(4-chlorophenyl)-1-[(1-cyanocyclopropyl)methoxy]-7-fluoro-5-(2-hydroxypropan-2-yl)-3-oxoisoindol-2-yl]methyl]benzoic acid Chemical compound ClC=1C=CC(=C(C(=O)O)C=1)CN1[C@@](C2=C(C=C(C=C2C1=O)C(C)(C)O)F)(OCC1(CC1)C#N)C1=CC=C(C=C1)Cl DEAVUDZEMMDBRA-SSEXGKCCSA-N 0.000 claims 1
- NQWVLAWWWVVUAN-SSEXGKCCSA-N 5-chloro-2-[[(1R)-1-(4-chlorophenyl)-1-[[1-(hydroxymethyl)cyclopropyl]methoxy]-5-(2-hydroxypropan-2-yl)-3-oxoisoindol-2-yl]methyl]benzoic acid Chemical compound ClC=1C=CC(=C(C(=O)O)C=1)CN1[C@@](C2=CC=C(C=C2C1=O)C(C)(C)O)(OCC1(CC1)CO)C1=CC=C(C=C1)Cl NQWVLAWWWVVUAN-SSEXGKCCSA-N 0.000 claims 1
- DLUFTCNJNCOQGS-AJQTZOPKSA-N 5-chloro-2-[[(1R)-1-(4-chlorophenyl)-1-ethoxy-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-3-oxoisoindol-2-yl]methyl]benzoic acid Chemical compound ClC=1C=CC(=C(C(=O)O)C=1)CN1[C@@](C2=C(C=C(C=C2C1=O)[C@](CC)(C1CCOCC1)O)F)(OCC)C1=CC=C(C=C1)Cl DLUFTCNJNCOQGS-AJQTZOPKSA-N 0.000 claims 1
- NOIABBKIABICFM-FIRIVFDPSA-N 5-chloro-2-[[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1R)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxoisoindol-2-yl]methyl]benzoic acid Chemical compound ClC=1C=CC(=C(C(=O)O)C=1)CN1[C@@](C2=C(C=C(C=C2C1=O)[C@@](CC)(C1CCOCC1)O)F)(OC)C1=CC=C(C=C1)Cl NOIABBKIABICFM-FIRIVFDPSA-N 0.000 claims 1
- NOIABBKIABICFM-IOWSJCHKSA-N 5-chloro-2-[[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxoisoindol-2-yl]methyl]benzoic acid Chemical compound ClC=1C=CC(=C(C(=O)O)C=1)CN1[C@@](C2=C(C=C(C=C2C1=O)[C@](CC)(C1CCOCC1)O)F)(OC)C1=CC=C(C=C1)Cl NOIABBKIABICFM-IOWSJCHKSA-N 0.000 claims 1
- PGUDRRCAMVOBPY-NLIBRCFJSA-N 5-chloro-2-[[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[1-hydroxy-1-(1-methylpiperidin-4-yl)ethyl]-1-methoxy-3-oxoisoindol-2-yl]methyl]benzoic acid Chemical compound ClC=1C=CC(=C(C(=O)O)C=1)CN1[C@@](C2=C(C=C(C=C2C1=O)C(C)(C1CCN(CC1)C)O)F)(OC)C1=CC=C(C=C1)Cl PGUDRRCAMVOBPY-NLIBRCFJSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 229940123407 Androgen receptor antagonist Drugs 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- IARKWVZHJYWTDX-WJOKGBTCSA-N CC(C)(O)C1=CC(F)=C2C(=C1)C(=O)N(CC1=C(C=C(Cl)C=C1)P(C)(C)=O)[C@@]2(OCC1(CO)CC1)C1=CC=C(Cl)C=C1 Chemical compound CC(C)(O)C1=CC(F)=C2C(=C1)C(=O)N(CC1=C(C=C(Cl)C=C1)P(C)(C)=O)[C@@]2(OCC1(CO)CC1)C1=CC=C(Cl)C=C1 IARKWVZHJYWTDX-WJOKGBTCSA-N 0.000 claims 1
- ONXUOCISKNKLEO-SSEXGKCCSA-N CCC1(CO[C@]2(N(CC3=CC=C(Cl)C=C3)C(=O)C3=CC(=CC=C23)C(C)(C)O)C2=CC=C(Cl)C=C2)CC1 Chemical compound CCC1(CO[C@]2(N(CC3=CC=C(Cl)C=C3)C(=O)C3=CC(=CC=C23)C(C)(C)O)C2=CC=C(Cl)C=C2)CC1 ONXUOCISKNKLEO-SSEXGKCCSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 108010077544 Chromatin Proteins 0.000 claims 1
- DIVMTXBUDOMYFO-XPXWJOHCSA-N ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC(=C12)F)C(C)(C)O)=O)CC1=CC=C(C#N)C=C1)OC([2H])([2H])C1(CC1)C([2H])([2H])O Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC(=C12)F)C(C)(C)O)=O)CC1=CC=C(C#N)C=C1)OC([2H])([2H])C1(CC1)C([2H])([2H])O DIVMTXBUDOMYFO-XPXWJOHCSA-N 0.000 claims 1
- RVEVEKZOUQPWSR-RYGNPJRDSA-N ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC(=C12)F)[C@](CC)(C1CCN(CC1)C)O)=O)CC1=CC=C(C#N)C=C1)O[C@@H]1C[C@@H](C1)O Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC(=C12)F)[C@](CC)(C1CCN(CC1)C)O)=O)CC1=CC=C(C#N)C=C1)O[C@@H]1C[C@@H](C1)O RVEVEKZOUQPWSR-RYGNPJRDSA-N 0.000 claims 1
- ZJSPHSZNTWLUQB-SUYBVONHSA-N ClC1=CC=C(C=C1)[C@H](CC(=O)O)N1[C@@](C2=CC=C(C=C2C1=O)C(C)(C)O)(OCC1(CC1)CO)C1=CC=C(C=C1)Cl Chemical compound ClC1=CC=C(C=C1)[C@H](CC(=O)O)N1[C@@](C2=CC=C(C=C2C1=O)C(C)(C)O)(OCC1(CC1)CO)C1=CC=C(C=C1)Cl ZJSPHSZNTWLUQB-SUYBVONHSA-N 0.000 claims 1
- QJTCYWYDSIOJFY-OYLRFEPJSA-N ClC1=CC=C(C=C1)[C@H](CCC(=O)O)N1[C@@](C2=C(C=C(C=C2C1=O)C(CC)([C@@H]1CC[C@H](CC1)O)O)F)(OC)C1=CC=C(C=C1)Cl Chemical compound ClC1=CC=C(C=C1)[C@H](CCC(=O)O)N1[C@@](C2=C(C=C(C=C2C1=O)C(CC)([C@@H]1CC[C@H](CC1)O)O)F)(OC)C1=CC=C(C=C1)Cl QJTCYWYDSIOJFY-OYLRFEPJSA-N 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 230000033616 DNA repair Effects 0.000 claims 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims 1
- 102000009058 Death Domain Receptors Human genes 0.000 claims 1
- 108010049207 Death Domain Receptors Proteins 0.000 claims 1
- 208000007033 Dysgerminoma Diseases 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 229940127462 Estrogen Synthesis Inhibitors Drugs 0.000 claims 1
- 229940102550 Estrogen receptor antagonist Drugs 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 239000007818 Grignard reagent Substances 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000006937 Hydatidiform mole Diseases 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 208000005890 Neuroma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033963 Parathyroid tumour Diseases 0.000 claims 1
- 208000007641 Pinealoma Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 1
- 102000004243 Tubulin Human genes 0.000 claims 1
- 108090000704 Tubulin Proteins 0.000 claims 1
- 229940122803 Vinca alkaloid Drugs 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000003936 androgen receptor antagonist Substances 0.000 claims 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 230000002280 anti-androgenic effect Effects 0.000 claims 1
- 230000003432 anti-folate effect Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 239000000051 antiandrogen Substances 0.000 claims 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims 1
- 229940127074 antifolate Drugs 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000003972 antineoplastic antibiotic Substances 0.000 claims 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 229940046844 aromatase inhibitors Drugs 0.000 claims 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 239000003719 aurora kinase inhibitor Substances 0.000 claims 1
- 210000003445 biliary tract Anatomy 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 208000002458 carcinoid tumor Diseases 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims 1
- 210000003483 chromatin Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 claims 1
- 201000011523 endocrine gland cancer Diseases 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 229930013356 epothilone Natural products 0.000 claims 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000003020 exocrine pancreas Anatomy 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 239000004052 folic acid antagonist Substances 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 210000005095 gastrointestinal system Anatomy 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 150000004795 grignard reagents Chemical group 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 229940047122 interleukins Drugs 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N isopropyl alcohol Natural products CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000002697 lyase inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- ATEBGPCVCPBSLM-SZAHLOSFSA-N methyl 3-[4-[(1S)-1-[(1R)-1-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-7-fluoro-1-methoxy-3-oxoisoindol-5-yl]-1-hydroxypropyl]piperidin-1-yl]propanoate Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC(=C12)F)[C@@](CC)(O)C1CCN(CC1)CCC(=O)OC)=O)CC1=CC=C(C=C1)Cl)OC ATEBGPCVCPBSLM-SZAHLOSFSA-N 0.000 claims 1
- 210000000754 myometrium Anatomy 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 210000001020 neural plate Anatomy 0.000 claims 1
- 208000007538 neurilemmoma Diseases 0.000 claims 1
- 229910052757 nitrogen Chemical group 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 125000002524 organometallic group Chemical group 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000003101 oviduct Anatomy 0.000 claims 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 210000003899 penis Anatomy 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 150000003058 platinum compounds Chemical class 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000001294 propane Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 238000011363 radioimmunotherapy Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 239000003277 telomerase inhibitor Substances 0.000 claims 1
- RGCRBSVSBVXCDO-LQFQNGICSA-N tert-butyl 2-[4-[(1R)-1-[(1R)-1-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-7-fluoro-1-methoxy-3-oxoisoindol-5-yl]-1-hydroxypropyl]piperidin-1-yl]acetate Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC(=C12)F)[C@](CC)(O)C1CCN(CC1)CC(=O)OC(C)(C)C)=O)CC1=CC=C(C=C1)Cl)OC RGCRBSVSBVXCDO-LQFQNGICSA-N 0.000 claims 1
- RGCRBSVSBVXCDO-MPQUPPDSSA-N tert-butyl 2-[4-[(1S)-1-[(1R)-1-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-7-fluoro-1-methoxy-3-oxoisoindol-5-yl]-1-hydroxypropyl]piperidin-1-yl]acetate Chemical compound ClC1=CC=C(C=C1)[C@@]1(N(C(C2=CC(=CC(=C12)F)[C@@](CC)(O)C1CCN(CC1)CC(=O)OC(C)(C)C)=O)CC1=CC=C(C=C1)Cl)OC RGCRBSVSBVXCDO-MPQUPPDSSA-N 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 229940021747 therapeutic vaccine Drugs 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 claims 1
- 208000017997 tumor of parathyroid gland Diseases 0.000 claims 1
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 210000003905 vulva Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (43)
1. Spoj formule (I):
[image]
,
ili njegov tautomer ili solvat ili farmaceutski prihvatljiva sol, naznačen time što:
R1 se neovisno bira između hidroksi, halogena, nitro, nitrila, C1-4alkila, halogenC1-4alkila, hidroksiC1-4alkila, C2-6alkenila, C1-4alkoksi, halogenC1-4alkoksi, C2-4alkinila, -O0,1-(CRxRy)v-CO2H, -(CRxRy)v-CO2C1-4alkila, -(CRxRy)v-CON(C1-4alkil)2, -P(=O)(Rx)2, -S(O)d-Rx, -S(O)d-heterocikličke skupine s 3 do 6 članova prstena i -S(O)d-N(R8)2;
R2 se bira između vodika, C1-4 alkila, C2-6alkenila, hidroksiC1-4alkila, -(CRxRy)u-CO2H, -(CRxRy)u-CO2C1-4alkila, te -(CRxRy)u-CONRxRy;
s se bira između 0 i 1;
R3 je vodik ili -(A)t-(CRxRy)q-X;
t se bira između 0 i 1;
q se bira između 0, 1 i 2;
gdje kada je R3 -(A)t-(CRxRy)q-X (i) najmanje jedan od s, t i q nije 0, te (ii) kada je t 0, s je 1, a q nije 0;
A je C3-6cikloalkilna skupina ili heterociklička skupina s 3 do 6 članova prstena, gdje heterociklička skupina sadrži jedan ili više heteroatoma, koje se bira između N, O, S i njihovih oksidiranih oblika;
X se bira između vodika, halogena, -CN, -OR9, -(CH2)v-CO2H, -(CH2)v-CO2C1-4alkil, -S(O)d-Rx, -C(=O)-C1-4alkil, -S(O)d-N(H)e(C1-4alkil)2-e, -NRxRy , -NHSO2Rx, -NRxCORy, te -C(=O)NRxRy;
R4 i R5 se neovisno bira između halogena, nitrila, C1-4 alkila, halogenC1-4alkila, C1-4alkoksi i halogenC1-4alkoksi;
R6 i R7 se neovisno bira između vodika, C1-6alkila, halogenC1-6alkila, C2-6alkenila, C2-6alkinila, hidroksi, hidroksiC1-6alkila, -COOC1-6alkila, -(CH2)j-O-C1-6alkila, -(CH2)j-O-(hidroksiC1-6alkil), -C1-6alkil-NRxRy, -(CRxRy)p-CONRxRy, -(CRxRy)p-NRxCORy, -(CRxRy)p-O-CH2-CONRxRy, heterocikličke skupine s 3 do 7 članova prstena, -CH2-heterocikličke skupine s 3 do 7 članova prstena, -CH2-O-heterocikličke skupine s 3 do 7 članova prstena, -CH2-NH-heterocikličke skupine s 3 do 7 članova prstena, -CH2-N(C1-6alkil)-heterocikličke skupine s 3 do 7 članova prstena, -C(=O)NH-heterocikličke skupine s 3 do 7 članova prstena, C3-8cikloalkila, -CH2-C3-8cikloalkila, -CH2-OC3-8cikloalkila, te C3-8cikloalkenila, gdje navedne cikloalkilne, cikloalkenilne ili heterocikličke skupine mogu biti izborno supstituirane s jednom ili više skupina Rz, te gdje u svakom slučaju heterociklička skupina sadrži jedan ili više heteroatoma, koje se bira između N, O, S i njihovih oksidiranih oblika;
ili skupine R6 i R7, zajedno s atomom ugljika na kojeg su vezane, se mogu spojiti kako bi tvorile C3-6cikloalkilnu ili heterociklilnu skupinu s 3 do 6 članova prstena, gdje heterociklička skupina sadrži jedan ili više heteroatoma, koje se bira između N, O, S i njihovih oksidiranih oblika, te gdje navedne C3-6cikloalkilne i heterociklilne skupine mogu biti izborno supstituirane s jednom ili više skupina Rz;
R8 i R9 se neovisno bira između vodika, C1-6alkila, halogenC1-6alkila, hidroksiC1-6alkila, -(CH2)k-OC1-6alkila, -(CH2)k-O-(hidroksiC1-6alkil), hidroksiC1-6alkoksi, -(CH2)k-CO2C1-6alkila, -(CH2)k-CO2H, -C1-6 alkil-N(H)e(C1-4alkil)2-e, -(CH2)j-C3-8cikloalkila i -(CH2)j-C3-8cikloalkenila;
Rx i Ry se neovisno bira između vodika, halogena, nitro, nitrila, C1-6alkil, halogenC1-6alkila, C2-6alkenila, C2-6alkinila, hidroksi, hidroksiC1-6alkila, C1-6alkoksi, -(CH2)k-O-C1-6alkila, hidroksiC1-6alkoksi, -COOC1-6alkila, -N(H)e(C1-4alkil)2-e, -C1-6alkil-N(H)e(C1-4alkil)2-e, -(CH2)k-C(=O)N(H)e(C1-4alkil)2-e, C3-8cikloalkila i C3-8cikloalkenila;
ili skupine Rx i Ry, zajedno s atomom ugljika ili dušika na kojeg su vezane, se mogu spojiti kako bi tvorile C3-6cikloalkilnu ili zasićenu heterociklilnu skupinu s 3 do 6 članova prstena, koja može biti izborno kondenzirana s aromatskom heterociklilnom skupinom s 3 do 5 članova prstena;
ili kada na atomu ugljika skupine Rx i Ry se mogu spojiti zajedno kako bi tvorile skupinu =CH2;
Rz se neovisno bira između halogena, nitro, nitrila, C1-6alkila, halogenC1-6alkila, C2-6alkenila, C2-6alkinila, =O, hidroksi, hidroksiC1-6alkila, C1-6alkoksi, -(CH2)k-O-C1-6alkila, hidroksiC1-6alkoksi, -C(=O)C1-6alkila, -C(=O)C1-6alkil-OH, -C(=O)C1-6alkil-N(H)e(C1-4alkil)2-e, -C(=O)N(H)e(C1-4alkil)2-e, -(CH2)r-CO2C1-6alkila, -(CH2)rCO2H, -N(H)e(C1-4alkil)2-e, -C1-6alkil-N(H)e(C1-4alkil)2-e, heterociklilne skupine s 3 do 6 članova prstena, heterociklilne skupine s 3 do 6 članova prstena, supstituirane s -C(=O)C1-4alkilom, heterociklilne skupine s 3 do 6 članova prstena, supstituirane s -C(=O)OC1-4alkilom, heterociklilne skupine s 3 do 6 članova prstena, supstituirane s -C(=O)N(H)e(C1-4alkil)2-e, -C(=O)heterociklilne skupine s 3 do 6 članova prstena, C3-8cikloalkila i C3-8cikloalkenila, gdje ako je R7 piridin, Rz nije -NH2;
a, j, d, e, n, r i p se neovisno bira između 0, 1 i 2;
k i m se neovisno bira između 1 i 2;
u se bira između 0, 1, 2 i 3; i
v se bira između 0 i 1.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što:
A je C3-6cikloalkilna skupina ili heterociklička skupina s 3 do 6 članova prstena, gdje heterociklička skupina sadrži 1, 2 ili 3 heteroatoma, koje se bira između N, O, S i njihovih oksidiranih oblika.
3. Spoj u skladu s patentnim zahtjevom 1 ili 2, naznačen time što:
R6 i R7 se neovisno bira između vodika, C1-6alkila, halogenC1-6alkila, C2-6alkenila, C2-6alkinila, hidroksi, hidroksiC1-6alkila, -COOC1-6alkila, -(CH2)j-O-C1-6alkila, -(CH2)j-O-(hidroksiC1-6alkil), -C1-6alkil-NRxRy, -(CRxRy)p-CONRxRy, -(CRxRy)p-NRxCORy, -(CRxRy)p-O-CH2-CONRxRy, heterocikličke skupine s 3 do 7 članova prstena, -CH2-heterocikličke skupine s 3 do 7 članova prstena, -CH2-O-heterocikličke skupine s 3 do 7 članova prstena, -CH2-NH-heterocikličke skupine s 3 do 7 članova prstena, -CH2-N(C1-6alkil)-heterocikličke skupine s 3 do 7 članova prstena, -C(=O)NH-heterocikličke skupine s 3 do 7 članova prstena, C3-8cikloalkila, -CH2-C3-8cikloalkila, -CH2-OC3-8cikloalkila, te C3-8cikloalkenila, gdje navedne cikloalkilne, cikloalkenilne ili heterocikličke skupine mogu biti izborno supstituirane s jednom ili više skupina Rz, te gdje u svakom slučaju heterociklička skupina sadrži 1, 2 ili 3 heteroatoma, koje se bira između N, O, S i njihovih oksidiranih oblika; ili
skupine R6 i R7, zajedno s atomom ugljika na kojeg su vezane, se mogu spojiti kako bi tvorile C3-6cikloalkilnu ili heterociklilnu skupinu s 3 do 6 članova prstena, gdje heterociklička skupina sadrži 1, 2 ili 3 heteroatoma, koje se bira između N, O, S i njihovih oksidiranih oblika, te gdje navedne C3-6cikloalkilne i heterociklilne skupine mogu biti izborno supstituirane s jednom ili više skupina Rz.
4. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što R1 je:
hidroksi, halogen, nitril, C1-4alkil, halogenC1-4alkil, hidroksiC1-4alkil, C2-6alkenil, C1-4alkoksi, halogenC1-4alkoksi, C2-4alkinil, -(CH2)v-CO2H, -(CRxRy)v-CO2C1-4alkil, -(CH2)v-CON(C1-4alkil)2, -P(=O)(Rx)2, -S(O)d-C1-6alkil, -S(O)d-heterociklička skupina s 3 do 6 članova prstena i -S(O)d-N(R8)2.
5. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što je R1 halogen, hidroksi, nitril, C1-4alkil, C2-4alkinil ili C1-4alkoksi.
6. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što je n 1, a R1 je klor ili nitril.
7. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što je R1 klor.
8. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je R2:
vodik, C1-4 alkil, C2-6alkenil ili hidroksiC1-4alkil, ili
-(CRxRy)u-CO2H.
9. Spoj u skladu s patentnim zahtjevom 8, naznačen time što se R2 bira između -COOH, -CH2COOH, -CH2CH2-CO2H, -(CH(CH3))-CO2H i -(C(CH3)2)-CO2H).
10. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je R3 -(A)t-(CRxRy)q-X, a A je bilo C3-6cikloalkilna skupina ili heterociklička skupina s 3 do 5 članova prstena.
11. Spoj u skladu s patentnim zahtjevom 10, naznačen time je A ciklopropilna skupina ili heterociklička skupina s 5 članova prstena.
12. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što je s 1.
13. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačen time što je X vodik, halogen, -CN, -OR9 ili -C(=O)NRxRy.
14. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je spoj formule (I) spoj formule:
[image]
,
ili njegov tautomer ili solvat ili farmaceutski prihvatljiva sol.
15. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 14, naznačen time što je spoj formule (I) spoj formule (Ir):
[image]
,
ili njegov tautomer ili solvat ili farmaceutski prihvatljiva sol.
16. Spoj u skladu s patentnim zahtjevom 15, naznačen time što je spoj spoj formule (Is):
[image]
,
ili njegov tautomer ili solvat ili farmaceutski prihvatljiva sol.
17. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 16, gdje je R5 klor, m je 1, a supstituent R5 je na para-položaju u fenilnoj skupini.
18. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 17, naznačen time što:
(i) R7 se bira između heterocikličke skupine s 3 do 7 članova prstena i -CH2-heterocikličke skupine s 3 do 7 članova prstena, gdje navedne heterocikličke skupine mogu biti izborno supstituirane s jednom ili više skupina Rz, te gdje u svakom slučaju heterociklička skupina sadrži jedan ili više heteroatoma, koje se bira između N, O, S i njihovih oksidiranih oblika; i/ili
(ii) R6 je metil ili etil.
19. Spoj u skladu s patentnim zahtjevom 18, naznačen time što se R7 bira između oksanila, piperidinila, pirazolila ili imidazolila, koji može biti supstituiran s jednim ili više Rz, gdje se Rz bira između halogena ili C1-4alkila.
20. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je spoj spoj formule (Vllf):
[image]
,
ili njegov tautomer ili solvat ili farmaceutski prihvatljiva sol, naznačen time što:
n je 1, a R1 je klor ili nitril;
R2 je vodik, C1-4alkil, ili -CH2COOH, -CH2CH2-CO2H ili -(CH(CH3))-CO2H;
R4 i R5 su halogen;
R6 je metil ili etil; i
R7 je oksanil, piperidinil, pirazolil ili imidazolil, koji može biti supstituiran s jednim ili više Rz, gdje je Rz halogen ili C1-4alkil.
21. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je spoj spoj formule (Iw):
[image]
,
ili njegov tautomer ili solvat ili farmaceutski prihvatljiva sol, gdje:
n je 1, a R1 je klor ili nitril;
R2 je vodik, C1-4 alkil, ili -CH2COOH, -CH2CH2-CO2H ili -(CH(CH3))-CO2H;
s je 1, a R3 je vodik;
R4 je halogen;
m je 1 ili 2, a R5 je halogen; i
Rz je vodik ili fluor.
22. Spoj formule (Iw) u skladu s patentnim zahtjevom 21, gdje R4 je fluor.
23. Spoj formule (I) u skladu s patentnim zahtjevom 1, ili njegov tautomer ili solvat ili farmaceutski prihvatljiva sol, naznačen time što:
n je 1 ili 2, a R1 je halogen, nitril ili -O0,1(CRxRy)vCOOH, gdje je v 0 ili 1;
R2 se bira između vodika i -(CRxRy)u-CO2H, gdje je u 0, 1 ili 2;
Rx i Ry su vodik ili metil;
R3 je vodik, a s je 1;
a je 1, a R4 je halogen;
m je 1, a R5 je halogen;
R6 je vodik ili C1-6alkil;
R7 je C1-4alkil, hidroksilC1-4alkil, metoksiC1-4alkil, ili heterociklička skupina s 5 ili 6 članova prstena, gdje navedna heterociklička skupina s 5 ili 6 članova prstena može biti izborno supstituirana s jednom ili dvije skupine Rz koje se neovisno bira između C1-4alkila.
24. Spoj u skladu s patentnim zahtjevom 1, ili njegov tautomer, farmaceutski prihvatljiva sol ili solvat, naznačen time što se spoj bira između:
(3R)-3-(4-klorfenil)-2-[(4-klorfenil)metil]-3-{[1-(hidroksimetil)ciklopropil]metoksi}-6-(2-hidroksipropan-2-il)-2,3-dihidro-1H-izoindol-1-ona;
(3R)-3-(4-klorfenil)-2-[(4-klorfenil)metil]-4-fluor-3-{[1-(hidroksimetil)ciklopropil]metoksi}-6-(2-hidroksipropan-2-il)-2,3-dihidro-1H-izoindol-1-ona;
(3R)-3-(4-klorfenil)-2-[(4-klorfenil)metil]-3-(2-hidroksietoksi)-6-(2-hidroksipropan-2-il)-2,3-dihidro-1H-izoindol-1-ona;
(3R)-3-(4-klorfenil)-2-[(4-klorfenil)metil]-3-{[3-(hidroksimetil)oksetan-3-il]metoksi}-6-(2-hidroksipropan-2-il)-2,3-dihidro-1H-izoindol-1-ona;
1-({[(1R)-1-(4-klorfenil)-2-[(4-klorfenil)metil]-5-(2-hidroksipropan-2-il)-3-okso-2,3-dihidro-1H-izoindol-1-il]oksi}metil)ciklopropan-1-karboksilne kiseline;
(3R)-3-(4-klorfenil)-2-[(1S)-1-(4-klorfenil)etil]-3-(2,3-dihidroksi-2-metilpropoksi)-6-(2-hidroksipropan-2-il)-2,3-dihidro-1H-izoindol-1-ona;
(3R)-3-(4-klorfenil)-2-[(1S)-1-(4-klorfenil)etil]-3-{[1-(hidroksimetil)ciklopropil]metoksi}-6-(2-hidroksipropan-2-il)-2,3-dihidro-1H-izoindol-1-ona;
(3R)-3-(4-klorfenil)-2-[(4-klorfenil)metil]-6-(1,2-dihidroksipropan-2-il)-3-{[1-(hidroksimetil)ciklopropil]metoksi}-2,3-dihidro-1H-izoindol-1-ona;
(3R)-3-(4-klorfenil)-2-[(1S)-1-(4-klorfenil)etil]-6-(2-hidroksi-1-metoksipropan-2-il)-3-{[1-(hidroksimetil)ciklopropil]metoksi}-2,3-dihidro-1H-izoindol-1-ona;
(3R)-3-(4-klorfenil)-2-[(4-klorfenil)metil]-6-[1-(dimetilamino)-2-hidroksipropan-2-il]-3-{[1-(hidroksimetil)ciklopropil]metoksi}-2,3-dihidro-1H-izoindol-1-ona;
(3S)-3-(4-klorfenil)-3-[(1R)-1-(4-klorfenil)-1-{[1-(hidroksimetil)ciklopropil]metoksi}-5-(2-hidroksipropan-2-il)-3-okso-2,3-dihidro-1H-izoindol-2-il]propanske kiseline;
(3R)-3-(4-klorfenil)-2-[(1S)-1-(4-klorfenil)etil]-6-(1,2-dihidroksipropan-2-il)-3-{[1-(hidroksimetil)ciklopropil]metoksi}-2,3-dihidro-1H-izoindol-1-ona;
(3R)-3-(4-klorfenil)-2-[(4-klorfenil)metil]-3-(3-hidroksi-3-metilbutoksi)-6-(2-hidroksipropan-2-il)-2,3-dihidro-1H-izoindol-1-ona;
(3R)-3-(4-klorfenil)-2-[(4-klorfenil)metil]-6-(2-hidroksipropan-2-il)-3-[(1H-pirazol-4-il)metoksi]-2,3-dihidro-1H-izoindol-1-ona;
1-({[(1R)-1-(4-klorfenil)-2-[(4-klorfenil)metil]-5-(2-hidroksipropan-2-il)-3-okso-2,3-dihidro-1H-izoindol-1-il]oksi}metil)ciklopropan-1-karbonitrila;
N-{[1-({[(1R)-1-(4-klorfenil)-2-[(4-klorfenil)metil]-5-(2-hidroksipropan-2-il)-3-okso-2,3-dihidro-1H-izoindol-1-il]oksi}metil)ciklopropil]metil}metansulfonamida;
(3R)-3-(4-klorfenil)-2-[(4-etinilfenil)metil]-3-{[1-(hidroksimetil)ciklopropil]metoksi}-6-(2-hidroksipropan-2-il)-2,3-dihidro-1H-izoindol-1-ona;
(3R)-3-(4-klorfenil)-2-[(4-etinilfenil)metil]-4-fluor-3-{[1-(hidroksimetil)ciklopropil]metoksi}-6-(2-hidroksipropan-2-il)-2,3-dihidro-1H-izoindol-1-ona;
(3R)-3-(4-klorfenil)-6-(1,2-dihidroksipropan-2-il)-2-[(4-etinilfenil)metil]-4-fluor-3-{[1-(hidroksimetil)ciklopropil]metoksi}-2,3-dihidro-1H-izoindol-1-ona;
4-{[(1R)-1-(4-klorfenil)-7-fluor-1-({1-[hidroksi(2H2)metil]ciklopropil)(2H2)metoksi)-5-(2-hidroksipropan-2-il)-3-okso-2,3-dihidro-1H-izoindol-2-il]metil}benzonitrila;
4-{[(1R)-1-(4-klorfenil)-1-{[1-(hidroksimetil)ciklopropil]metoksi}-5-(2-hidroksipropan-2-il)-3-okso-2,3-dihidro-1H-izoindol-2-il]metil}benzonitrila;
(3R)-3-(4-klorfenil)-2-[(4-klorfenil)metil]-6-(2-hidroksipropan-2-il)-3-[(3-metiloksetan-3-il)metoksi]-2,3-dihidro-1H-izoindol-1-ona;
4-{[(1R)-1-(4-klorfenil)-5-(1,2-dihidroksipropan-2-il)-1-{[1-(hidroksimetil)ciklopropil]metoksi}-3-okso-2,3-dihidro-1H-izoindol-2-il]metil}benzonitrila;
(3R)-3-(4-klorfenil)-2-[(4-klorfenil)metil]-3-[(1-hidroksikiklopropil)metoksi]-6-(2-hidroksipropan-2-il)-2,3-dihidro-1H-izoindol-1-ona;
(3R)-3-(4-klorfenil)-2-[(4-klorfenil)metil]-6-(2-hidroksipropan-2-il)-3-{[1-(metoksimetil)ciklopropil]metoksi}-2,3-dihidro-1H-izoindol-1-ona;
(3R)-3-(4-klorfenil)-2-[(4-klorfenil)metil]-3-{[1-(hidroksimetil)ciklobutil]metoksi}-6-(2-hidroksipropan-2-il)-2,3-dihidro-1H-izoindol-1-ona;
5-klor-2-{[(1R)-1-(4-klorfenil)-1-{[1-(hidroksimetil)ciklopropil]metoksi}-5-(2-hidroksipropan-2-il)-3-okso-2,3-dihidro-1H-izoindol-2-il]metil)benzojeve kiseline;
(3R)-2-{[4-klor-2-(morfoline-4-sulfonil)fenil]metil}-3-(4-klorfenil)-3-{[1-(hidroksimetil)ciklopropil]metoksi}-6-(2-hidroksipropan-2-il)-2,3-dihidro-1H-izoindol-1-ona;
1-({[(1R)-2-[(4-klor-2-metansulfonilfenil)metil]-1-(4-klorfenil)-7-fluor-5-(2-hidroksipropan-2-il)-3-okso-2,3-dihidro-1H-izoindol-1-il]oksi}metil)ciklopropan-1-karboksamida;
(3R)-2-[(4-klor-2-metansulfonilfenil)metil]-3-(4-klorfenil)-3-({1-[hidroksi(2H2)metil]ciklopropil}(2H2)metoksi)-6-(2-hidroksipropan-2-il)-2,3-dihidro-1H-izoindol-1-ona;
(3R)-3-(4-klorfenil)-2-[(4-klorfenil)metil]-6-(2-hidroksipropan-2-il)-3-(oksolan-3-iloksi)-2,3-dihidro-1H-izoindol-1-ona;
(3R)-3-(4-klorfenil)-2-[(4-klorfenil)metil]-6-(2-hidroksipropan-2-il)-3-[(oksolan-3-il)metoksi]-2,3-dihidro-1H-izoindol-1-ona;
(3R)-2-[(4-klor-2-metansulfonilfenil)metil]-3-(4-klorfenil)-4-fluor-6-[1-hidroksi-1-(oksan-4-il-(hidroksimetil)ciklopropil]metoksi}-2,3-dihidro-1H-izoindol-1-ona;
(3R)-2-[(4-klor-2-metansulfonilfenil)metil]-3-(4-klorfenil)-4-fluor-6-[2-hidroksi-1-(piperazin-1-il)propan-2-il]-3-{[1-(hidroksimetil)ciklopropil]metoksi}-2,3-dihidro-1H-izoindol-1-ona;
(3R)-3-(4-klorfenil)-2-[(1S)-1-(4-klorfenil)etil]-3-{[(3S,4R)-4-hidroksioksolan-3-il]oksi}-6-(2-hidroksipropan-2-il)-2,3-dihidro-1H-izoindol-1-ona;
(3R)-3-(4-klorfenil)-2-[(1S)-1-(4-klorfenil)etil]-3-{[(3R,4S)-4-hidroksioksolan-3-il]oksi}-6-(2-hidroksipropan-2-il)-2,3-dihidro-1H-izoindol-1-ona;
(3R)-3-(4-klorfenil)-2-[(4-klorfenil)metil]-6-(2-hidroksipropan-2-il)-3-metoksi-2,3-dihidro-1H-izoindol-1-ona;
(3R)-3-(4-klorfenil)-2-[(4-klorfenil)metil]-3-({1-[hidroksi(2H2)metil]ciklopropil}(2H2)metoksi)-6-(2-hidroksipropan-2-il)-2,3-dihidro-1H-izoindol-1-ona;
(3R)-3-(4-klorfenil)-2-[(4-klorfenil)metil]-6-(2-hidroksipropan-2-il)-3-(3-hidroksipropoksi)-2,3-dihidro-1H-izoindol-1-ona;
(3R)-2-[(4-klor-2-metansulfonilfenil)metil]-3-(4-klorfenil)-4-fluor-3-{[1-(hidroksimetil)ciklopropil]metoksi}-6-(2-hidroksipropan-2-il)-2,3-dihidro-1H-izoindol-1-ona;
(3R)-3-(4-klorfenil)-2-[(4-klorfenil)metil]-3-(2,2-difluor-3-hidroksipropoksi)-6-(2-hidroksipropan-2-il)-2,3-dihidro-1H-izoindol-1-ona;
(3R)-3-(4-klorfenil)-2-[(4-klorfenil)metil]-3-{[2-(hidroksimetil)ciklobutil]metoksi}-6-(2-hidroksipropan-2-il)-2,3-dihidro-1H-izoindol-1-ona;
(3R)-3-(4-klorfenil)-2-[(4-klorfenil)metil]-6-[2-hidroksi-1-okso-1-(pirrolidin-1-il)propan-2-il]-3-{[1-(hidroksimetil)ciklopropil]metoksi}-2,3-dihidro-1H-izoindol-1-ona;
2-[(1R)-1-(4-klorfenil)-2-[(4-klorfenil)metil]-1-{[1-(hidroksimetil)ciklopropil]metoksi}-3-okso-2,3-dihidro-1H-izoindol-5-il]-2-hidroksi-N,N-dimetilpropanamida;
2-[(1R)-1-(4-klorfenil)-2-[(4-klorfenil)metil]-1-{[1-(hidroksimetil)ciklopropil]metoksi}-3-okso-2,3-dihidro-1H-izoindol-5-il]-2-hidroksi-N-metilpropanamida;
(3R)-2-{[4-klor-2-(metilsulfanil)fenil]metil}-3-(4-klorfenil)-4-fluor-3-{[1-(hidroksimetil)ciklopropil]metoksi}-6-(2-hidroksipropan-2-il)-2,3-dihidro-1H-izoindol-1-ona;
(3R)-2-[(4-klor-2-metanesulfinilfenil)metil]-3-(4-klorfenil)-4-fluor-3-{[1-(hidroksimetil)ciklopropil]metoksi}-6-(2-hidroksipropan-2-il)-2,3-dihidro-1H-izoindol-1-ona;
(3R)-2-[(4-klor-2-metansulfonilfenil)metil]-3-(4-klorfenil)-4-fluor-6-(2-hidroksi-1-metoksipropan-2-il)-3-{[1-(hidroksimetil)ciklopropil]metoksi}-2,3-dihidro-1H-izoindol-1-ona;
(3R)-2-[(4-klor-2-metansulfonilfenil)metil]-3-(4-klorfenil)-6-(1,2-dihidroksipropan-2-il)-4-fluor-3-{[1-(hidroksimetil)ciklopropil]metoksi}-2,3-dihidro-1H-izoindol-1-ona;
(3R)-2-[(4-klor-2-metansulfonilfenil)metil]-3-(4-klorfenil)-4-fluor-6-[2-hidroksi-1-(4-metilpiperazin-1-il)propan-2-il]-3-[(3R)-oksolan-3-iloksi]-2,3-dihidro-1H-izoindol-1-ona;
(3R)-2-[(4-klor-2-metansulfonilfenil)metil]-3-(4-klorfenil)-4-fluor-6-[2-hidroksi-1-(4-metilpiperazin-1-il)propan-2-il]-3-[(3S)-oksolan-3-iloksi]-2,3-dihidro-1H-izoindol-1-ona;
(3S)-3-(4-klorfenil)-3-[(1R)-1-(4-klorfenil)-7-fluor-5-(2-hidroksipropan-2-il)-3-okso-1-[(3S)-oksolan-3-iloksi]-2,3-dihidro-1H-izoindol-2-il]propanske kiseline;
1-({[(1R)-2-{[4-klor-2-(hidroksimetil)fenil]metil}-1-(4-klorfenil)-7-fluor-5-(2-hidroksipropan-2-il)-3-okso-2,3-dihidro-1H-izoindol-1-il]oksi}metil)ciklopropan-1-karbonitrila;
1-({[(1R)-2-[(4-klor-2-metansulfonilfenil)metil]-1-(4-klorfenil)-7-fluor-5-[1-hidroksi-1-(1-metil-1H-pirazol-4-il)etil]-3-okso-2,3-dihidro-1H-izoindol-1-il]oksi}metil)ciklopropan-1-karboksamida;
(3R)-2-[(4-klor-2-metansulfonilfenil)metil]-3-(4-klorfenil)-4-fluor-6-[1-hidroksi-1-(1-metil-1H-pirazol-4-il)etil]-3-[(1-hidroksikiklopropil)metoksi]-2,3-dihidro-1H-izoindol-1-ona;
(3R)-2-[(4-klor-2-metansulfonilfenil)metil]-3-(4-klorfenil)-4-fluor-6-[2-hidroksi-1-(4-metilpiperazin-1-il)propan-2-il]-3-{[1-(hidroksimetil)ciklopropil]metoksi}-2,3-dihidro-1H-izoindol-1-ona;
5-klor-2-{[(1R)-1-(4-klorfenil)-1-[(1-cijanociklopropil)metoksi]-7-fluor-5-(2-hidroksipropan-2-il)-3-okso-2,3-dihidro-1H-izoindol-2-il]metil}benzojeve kiseline;
(3R)-2-[(4-klor-2-metansulfonilfenil)metil]-3-(4-klorfenil)-4-fluor-6-[1-hidroksi-1-(1-metilpiperidin-4-il)etil]-3-{[1-(hidroksimetil)ciklopropil]metoksi}-2,3-dihidro-1H-izoindol-1-ona;
(3R)-2-{[4-klor-2-(dimetilfosforil)fenil]metil}-3-(4-klorfenil)-4-fluor-3-{[1-(hidroksimetil)ciklopropil]metoksi}-6-(2-hidroksipropan-2-il)-2,3-dihidro-1H-izoindol-1-ona;
(3R)-2-[(4-klor-2-metansulfonilfenil)metil]-3-(4-klorfenil)-4-fluor-6-[hidroksi(oksan-4-il)metil]-3-{[1-(hidroksimetil)ciklopropil]metoksi}-2,3-dihidro-1H-izoindol-1-ona;
1-({[(1R)-2-[(4-klor-2-metansulfonilfenil)metil]-1-(4-klorfenil)-7-fluor-5-[1-hidroksi-1-(oksan-4-il)etil]-3-okso-2,3-dihidro-1H-izoindol-1-il]oksi}metil)ciklopropan-1-karboksamida;
5-klor-2-{[(1R)-1-(4-klorfenil)-7-fluor-5-[1-hidroksi-1-(1-metilpiperidin-4-il)etil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]metil}benzojeve kiseline;
(3S)-3-(4-klorfenil)-3-[(1R)-1-(4-klorfenil)-7-fluor-5-[1-hidroksi-1-(oksan-4-il)etil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]propanske kiseline;
4-[(1R)-1-[(1R)-1-(4-klorfenil)-7-fluor-5-[1-hidroksi-1-(1-metil-1H-imidazol-4-il)propil]-3-okso-1-[(3S)-oksolan-3-iloksi]-2,3-dihidro-1H-izoindol-2-il]-2-hidroksietil]benzonitrila;
4-{[(1R)-1-(4-klorfenil)-7-fluor-5-[1-hidroksi-1-(1-metil-1H-imidazol-4-il)propil]-3-okso-1-[(3S)-oksolan-3-iloksi]-2,3-dihidro-1H-izoindol-2-il]metil}-3-(hidroksimetil)benzonitrila;
4-{[(1R)-1-(4-klorfenil)-7-fluor-5-[1-hidroksi-1-(1-metil-1H-imidazol-4-il)propil]-1-{[1-(hidroksimetil)ciklopropil]metoksi}-3-okso-2,3-dihidro-1H-izoindol-2-il]metil}benzonitrila;
4-{[(1R)-1-(4-klorfenil)-7-fluor-5-[1-hidroksi-1-(1-metil-1H-imidazol-4-il)propil]-3-okso-1-[(3S)-oksolan-3-iloksi]-2,3-dihidro-1H-izoindol-2-il]metil}benzonitrila;
(3S)-3-(4-klorfenil)-3-[(1-R)-1-(4-klorfenil)-7-fluor-5-[1-(4-fluoroksan-4-il)-1-hidroksietil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]propanske kiseline;
(4S)-4-(4-klorfenil)-4-[(1R)-1-(4-klorfenil)-7-fluor-5-[1-hidroksi-1-(1-metil-1H-pirazol-3-il)propil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]butanske kiseline;
(3S)-3-(4-klorfenil)-3-[(1-R)-1-(4-klorfenil)-7-fluor-5-[1-(4-fluoroksan-4-il)-1-hidroksipropil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]propanske kiseline;
(3S)-3-(4-klorfenil)-3-[(1R)-1-(4-klorfenil)-5-(1-ciklobutil-1-hidroksietil)-7-fluor-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]propanske kiseline;
(3S)-3-(4-klorfenil)-3-[(1R)-1-(4-klorfenil)-7-fluor-5-[(1S)-1-hidroksi-1-(oksan-4-il)propil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]propanske kiseline;
(3S)-3-(4-klorfenil)-3-[(1R)-1-(4-klorfenil)-7-fluor-5-[(1R)-1-hidroksi-1-(oksan-4-il)propil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]propanske kiseline;
(4S)-4-(4-klorfenil)-4-[(1R)-1-(4-klorfenil)-7-fluor-5-[(1S)-1-hidroksi-1-(oksan-4-il)propil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]butanske kiseline;
(4S)-4-(4-klorfenil)-4-[(1R)-1-(4-klorfenil)-7-fluor-5-[(1R)-1-hidroksi-1-(oksan-4-il)propil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]butanske kiseline;
(4S)-4-(4-klorfenil)-4-[(1R)-1-(4-klorfenil)-7-fluor-5-[(1R)-1-(4-fluoroksan-4-il)-1-hidroksipropil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]butanske kiseline;
(3S)-3-(4-klorfenil)-3-[(1R)-1-(4-klorfenil)-7-fluor-5-[(1R)-1-(4-fluoroksan-4-il)-1-hidroksipropil]-1-trideuterometoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]propanske kiseline;
(3S)-3-(4-klorfenil)-3-[(1R)-1-(4-klorfenil)-1-etoksi-7-fluor-5-[(1R)-1-(4-fluoroksan-4-il)-1-hidroksipropil]-3-okso-2,3-dihidro-1H-izoindol-2-il]propanske kiseline;
(4S)-4-[(1R)-1-(4-klorfenil)-7-fluor-5-[(1R)-1-(4-fluoroksan-4-il)-1-hidroksipropil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]-4-(4-metoksifenil)butanske kiseline;
(4S)-4-(4-klorfenil)-4-[(1R)-1-(4-klorfenil)-7-fluor-5-{1-hidroksi-1-[trans-4-hidroksikikloheksil]propil}-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]butanske kiseline;
2-(5-klor-2-{[1-(4-klorfenil)-7-fluor-5-[(1R)-1-(4-fluoroksan-4-il)-1-hidroksipropil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]metil}fenoksi)octene kiseline;
5-klor-2-{[(1R)-1-(4-klorfenil)-7-fluor-5-[(1S)-1-hidroksi-1-(oksan-4-il)propil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]metil}benzojeve kiseline;
5-klor-2-{[(1R)-1-(4-klorfenil)-7-fluor-5-[(1R)-1-hidroksi-1-(oksan-4-il)propil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]metil}benzojeve kiseline;
5-klor-2-{[(1R)-1-(4-klorfenil)-1-etoksi-7-fluor-5-[(1S)-1-hidroksi-1-(oksan-4-il)propil]-3-okso-2,3-dihidro-1H-izoindol-2-il]metil}benzojeve kiseline;
2-{[(1R)-1-(4-klorfenil)-7-fluor-5-[(1R)-1-(4-fluoroksan-4-il)-1-hidroksipropil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]metil}-5-metilbenzojeve kiseline;
2-{[(1R)-1-(4-klorfenil)-7-fluor-5-[(1R)-1-(4-fluoroksan-4-il)-1-hidroksipropil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]metil}-5-metoksibenzojeve kiseline;
2-(5-klor-2-{[(1R)-1-(4-klorfenil)-7-fluor-5-[(1S)-1-hidroksi-1-(oksan-4-il)propil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]metil}fenil)-2-metilpropanske kiseline;
2-(5-klor-2-{[(1R)-1-(4-klorfenil)-7-fluor-5-[(1S)-1-hidroksi-1-(oksan-4-il)propil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]metil}fenil)octene kiseline;
2-(5-klor-2-{[(1R)-1-(4-klorfenil)-7-fluor-5-[(1R)-1-hidroksi-1-(oksan-4-il)propil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]metil}fenil)octene kiseline;
(2S,3S)-3-(4-klorfenil)-3-[(1R)-1-(4-klorfenil)-7-fluor-5-[(1S)-1-hidroksi-1-(oksan-4-il)propil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]-2-metilpropanske kiseline;
(3S)-3-(4-klorfenil)-3-[(1R)-1-(4-klorfenil)-7-fluor-1-[(3-fluoroksetan-3-il)metoksi]-5-(2-hidroksibutan-2-il)-3-okso-2,3-dihidro-1H-izoindol-2-il]propanske kiseline;
(3S)-3-(4-klorfenil)-3-[(1R)-1-(4-klorfenil)-7-fluor-5-[1-hidroksi-1-(piridin-2-il)propil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]propanske kiseline;
(3R)-2-[(4-klor-2-metansulfonilfenil)metil]-3-(4-klorfenil)-4-fluor-6-[1-(4-fluorpiperidin-4-il)-1-hidroksipropil]-3-metoksi-2,3-dihidro-1H-izoindol-1-ona;
4-{[(1R)-1-(4-klorfenil)-7-fluor-5-[(1S)-1-hidroksi-1-(1-metilpiperidin-4-il)propil]-3-okso-1-[cis-3-hidroksikiklobutoksi]-2,3-dihidro-1H-izoindol-2-il]metil}benzonitrila;
(3S)-3-(4-klorfenil)-3-[(1R)-1-(4-klorfenil)-7-fluor-5-[1-(4-fluor-1-metilpiperidin-4-il)-1-hidroksipropil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]propanske kiseline;
tert-butil-2-{4-[(1S)-1-[(1R)-1-(4-klorfenil)-2-[(4-klorfenil)metil]-7-fluor-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-5-il]-1-hidroksipropil]piperidin-1-il}acetata;
tert-butil-2-{4-[(1R)-1-[(1R)-1-(4-klorfenil)-2-[(4-klorfenil)metil]-7-fluor-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-5-il]-1-hidroksipropil]piperidin-1-il}acetata;
2-{4-[(1S)-1-[(1R)-1-(4-klorfenil)-2-[(4-klorfenil)metil]-7-fluor-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-5-il]-1-hidroksipropil]piperidin-1-il}octene kiseline;
2-{4-[(1R)-1-[(1R)-1-(4-klorfenil)-2-[(4-klorfenil)metil]-7-fluor-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-5-il]-1-hidroksipropil]piperidin-1-il}octene kiseline;
metil-3-{4-[(1S)-1-[(1R)-1-(4-klorfenil)-2-[(4-klorfenil)metil]-7-fluor-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-5-il]-1-hidroksipropil]piperidin-1-il}propanoata; i
3-{4-[(1S)-1-[(1R)-1-(4-klorfenil)-2-[(4-klorfenil)metil]-7-fluor-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-5-il]-1-hidroksipropil]piperidin-1-il}propanske kiseline.
25. Spoj, ili njegov tautomer, farmaceutski prihvatljiva sol ili solvat, naznačen time što je spoj 2-{[(1R)-1-(4-klorfenil)-2-[(4-klorfenil)metil]-5-(2-hidroksipropan-2-il)-3-okso-2,3-dihidro-1H-izoindol-1-il]oksi}-N,N-dimetilacetamid.
26. Spoj u skladu s patentnim zahtjevom 1, ili njegov tautomer, farmaceutski prihvatljiva sol ili solvat, naznačen time što je spoj (2S,3S)-3-(4-klorfenil)-3-[(1R)-1-(4-klorfenil)-7-fluor-5-[(1S)-1-hidroksi-1-(oksan-4-il)propil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]-2-metilpropanska kiselina.
27. Spoj u skladu s patentnim zahtjevom 1, ili njegov tautomer, farmaceutski prihvatljiva sol ili solvat, naznačen time što je spoj (3S)-3-(4-klorfenil)-3-[(1R)-1-(4-klorfenil)-7-fluor-5-[1-hidroksi-1-(oksan-4-il)etil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]propanska kiselina.
28. Spoj u skladu s patentnim zahtjevom 1, ili njegov tautomer, farmaceutski prihvatljiva sol ili solvat, naznačen time što je spoj 2-(5-klor-2-{[(1R)-1-(4-klorfenil)-7-fluor-5-[(1S)-1-hidroksi-1-(oksan-4-il)propil]-1-metoksi-3-okso-2,3-dihidro-1H-izoindol-2-il]metil}fenil)-2-metilpropanska kiselina.
29. Spoj u skladu s patentnim zahtjevom 1, ili njegov tautomer, farmaceutski prihvatljiva sol ili solvat, naznačen time što je spoj 4-{[(1R)-1-(4-klorfenil)-7-fluor-5-[1-hidroksi-1-(1-metil-1H-imidazol-4-il)propil]-1-{[1-(hidroksimetil)ciklopropil]metoksi}-3-okso-2,3-dihidro-1H-izoindol-2-il]metil}benzonitril.
30. Kombinacija, naznačena time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 29 uz jedno ili više drugih terapijskih sredstava.
31. Kombinacija u skladu s patentnim zahtjevom 30, naznačena time što su jedno ili više drugih terapijskih sredstava protutumorska sredstva.
32. Kombinacija u skladu s patentnim zahtjevom 30 ili 31, naznačena time što se jedno ili više drugih terapijskih sredstava bira iz skupina (i) do (xlix), kao što je definirano niže:
(i) spojeva platine;
(ii) taksanskih spojeva;
(iii) inhibitora topoizomeraze I;
(iv) inhibitora topoizomeraze II;
(v) vinka alkaloida;
(vi) nukleozidnih derivata;
(vii) antimetabolita;
(viii) alkilirajućih sredstava;
(ix) antraciklina i antracendiona;
(x) epotiloni;
(xi) inhibitora DNA-metil-transferaze;
(xii) antifolata;
(xiii) citotoksičnih antibiotika;
(xiv) sredstava koja se vežu na tubulin;
(xv) inhibitora prijenosa signala;
(xvi) inhibitora aurora kinaze;
(xvii) inhibitora CDK;
(xviii) inhibitora PKA/B i inhibitora PKB (akt) puta;
(xix) inhibitora hsp90;
(xx) monoklonskih protutijela (nekonjugiranih ili konjugiranih s radioizotopima, toksinima ili drugim sredstvima) i protutijelo derivati;
(xxi) antagonista estrogenskih receptora ili selektivnih modulatora estrogenskih receptora (SERM) ili inhibitora sinteze estrogena;
(xxii) inhibitora aromataze;
(xxiii) antiandrogena (tj. antagonista androgenskih receptora);
(xxiv) hormona i njihovih analoga;
(xxv) steroida;
(xxvi) inhibitora 17α-hidroksilaza-17,20-lijaze steroidnog citokroma P450 (CYP17);
(xxvii) agonista ili antagonista hormona oslobađanja gonadotropina (GnRA);
(xxviii) glukokortikoida;
(xxix) diferencirajućih sredstava;
(xxx) inhibitorai farnezil-transferaze;
(xxxi) terapije koja cilja na kromatin;
(xxxii) lijekova koji ciljaju na ubikvitinsko-proteasomni put, uključujući inhibitore proteasoma;
(xxxiii) fotodinamičkih lijekova;
(xxxiv) protutumorskih sredstava dobivenih iz morskih organizama;
(xxxv) radioaktivno obilježnih lijekova, namijenjenih radioimunoterapiji;
(xxxvi) inhibitora telomeraze;
(xxxvii) inhibitora matričnih metaloproteinaza;
(xxxviii) rekombinantnih interferona i interleukina;
(xxxix) modulatora selektivnog imunosnog odgovora;
(xl) terapijskih cjepiva;
(xli) sredstava koja aktiviraju citokine;
(xlii) arsenovog trioksida;
(xliii) inhibitora receptora spregnutih s G-proteinom (GPCR);
(xliv) enzimi;
(xlv) inhibitora popravka DNA;
(xlvi) agonista receptora za staničnu smrt;
(xlvii) imunoterapije;
(xlviii) regulatora antagonista stanične smrti (apoptoze);
(xlix) profilaktičkih sredstava (pomoćnih tvari).
33. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 29 ili kombinaciju u skladu s bilo kojim od patentnih zahtjeva 30 do 32.
34. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 29 i farmaceutski prihvatljivi nosač.
35. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 29, jedno ili više drugih terapijskih sredstava, kao i farmaceutski prihvatljivi nosač.
36. Farmaceutski pripravak u skladu s patentnim zahtjevom 35, naznačen time što su jedno ili više drugih terapijskih sredstava protutumorska sredstva.
37. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 29, ili njegov tautomer ili solvat ili farmaceutski prihvatljiva sol, naznačena time što je spoj namijenjen proizvodnji medikamenta namijenjenog upotrebi u profilaksi ili liječenju raka.
38. Upotreba u skladu s patentnim zahtjevom 37, naznačena time što se spoj upotrebljava u kombinaciji s jednim ili više drugih spojeva ili terapija.
39. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 29, kombinacija u skladu s bilo kojim od patentnih zahtjeva 30 do 32, ili farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 33 do 36, naznačeni time što su namijenjen upotrebi u:
– terapiji;
– profilaksi ili liječenju raka kod kojeg posreduje MDM2-p53;
– profilaksi ili liječenju raka; ili
– profilaksi ili liječenju raka, gdje se spoj upotrebljava u kombinaciji s jednim ili više drugih spojeva ili terapija.
40. Spoj, kombinacija farmaceutskog pripravka namijenjen upotrebi u profilaksi ili liječenju raka u skladu s patentnim zahtjevom 39, naznačen time što je jedan od jednog ili više drugih spojeva ili terapija radioterapija.
41. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 29, kombinacija u skladu s bilo kojim od patentnih zahtjeva 30 do 32, ili farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 33 do 36, naznačeni time što su namijenjeni upotrebi u profilaksi ili liječenju raka, gdje je rak:
– tumori epitelnog podrijetla; hematološki malignomi i prekancerozni hematološki poremećaji i poremećaji granične zloćudnosti; tumori mezenhimnog podrijetla; tumori središnjeg ili perifernog živčanog sustava; endokrino tumori; očni i tumori njegovih pomoćnih organa; tumori zametnih stanica i trofoblasta; pedijatrijski i embrionalni tumori; ili sindromi, prirođeni ili drugi, koji pacijenta čine sklonog zloćudnostima;
– karcinomi mokraćnog mjehura i mokraćnog sustava, dojke, gastrointestinalnog sustava, jetre, žučnog mjehura i žučnog sustava, egzokrine gušterače, bubrega, pluća, glave i vrata, jajnika, jajovoda, potrbušnice, vagine, vulve, penisa, testisa, vrata maternice, miometrija, endometrija, štitnjače, mozga, nadbubrežne žlijezde, prostate, kože ili njenih pomoćnih organa;
– hematološki malignomi i srodna stanja limfoidne loze, te hematološki malignomi i srodna stanja mijeloidne loze;
– sarkomi mekog tkiva, kosti ili hrskavice; astrocitomi, neuromi i glioblastomi, meningiomi, ependimomi, tumori epifize i švanomi; tumori hipofize, tumori nadbubrežne žlijezde, tumori stanica Langerhansovih otočića, tumori nusštitnjače, karcinoidni tumori i medularni karcinom štitnjače; retinoblastom; teratomi, seminomi, disgerminomi, hidatidiformni madeži i koriokarcinomi; meduloblastom, neuroblastom, Wilmsov tumor, te tumori primitivnog neuroektoderma; ili pigmentna kseroderma;
– leukemija;
– akutna mijeloidna leukemija (AML), akutna limfocitna leukemija (ALL), kronična limfocitna leukemija (CLL) ili kronična mijeloidna leukemija (CML);
– limfom;
– Burkittov limfom, Hodgkinov limfom, nehodgkinovski limfom ili difuzni limfom velikih B-stanica;
– tumor na mozgu, rak kože, rak pluća, rak gastrointestinalnog sustava, osteosarkom, liposarkom, Ewingov sarkom, sarkom mekog tkiva, rak jednjaka, kolorektanlni rak, rak dojke, rak pluća, rak na mozgu ili pedijatrijski rak;
– hepatocelularni karcinom, rak pluća, sarkomi, osteosarkomi ili Hodgkinova bolest;
– gliom ili neuroblastom;
– melanom;
– mezoteliom;
– zloćudni mezoteliom potrbušnice ili zloćudni mezoteliom poplućnice;
– GIST, rak želuca, kolorektanlni rak, rak debelog crijeva ili rak crijeva; ili
– fibrosarkom.
42. Postupak priprave spoja formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 24, ili 26 do 29, naznačen time što se sastoji u:
(a) reakciji spoja sljedeće formule s organometanilnim reagensom formule R6M (gdje je M metal):
[image]
,
gdje su R1, R2, R3, R4, R5, R6, R7, a, s, m i n u skladu s bilo kojim od patentnih zahtjeva 1 do 23; i/ili
(b) interkonverziji spoja formule (I), ili njegovog zaštićenog derivata, u daljnji spoj formule (I) ili, njegov zaštićeni derivat; i/ili
(c) uklanjanju zaštite sa zaštićenog derivata spoja formule (I); i/ili
(d) pripravi spoja formule (I) i dobivanju farmaceutski prihvatljive soli tog spoja.
43. Postupak u skladu s patentnim zahtjevom 42, naznačen time što je organometalni reagens Grignardov reagens formule R6MgBr.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1517217.4A GB201517217D0 (en) | 2015-09-29 | 2015-09-29 | Pharmaceutical compounds |
EP16777770.5A EP3356350B1 (en) | 2015-09-29 | 2016-09-29 | Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity |
PCT/GB2016/053042 WO2017055860A1 (en) | 2015-09-29 | 2016-09-29 | Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20221487T1 true HRP20221487T1 (hr) | 2023-02-03 |
Family
ID=54544291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20221487TT HRP20221487T1 (hr) | 2015-09-29 | 2016-09-29 | Izoindolinonski inhibitori međudjelovanja mdm2-p53 s protuumorskom aktivnošću |
Country Status (27)
Country | Link |
---|---|
US (3) | US10544132B2 (hr) |
EP (2) | EP3356350B1 (hr) |
JP (2) | JP7029387B2 (hr) |
KR (1) | KR20180081706A (hr) |
CN (2) | CN108290871B (hr) |
AU (2) | AU2016330030C1 (hr) |
BR (1) | BR112018005932B1 (hr) |
CA (1) | CA2999400A1 (hr) |
DK (1) | DK3356350T3 (hr) |
ES (1) | ES2934181T3 (hr) |
FI (1) | FI3356350T3 (hr) |
GB (1) | GB201517217D0 (hr) |
HK (1) | HK1250715A1 (hr) |
HR (1) | HRP20221487T1 (hr) |
HU (1) | HUE060638T2 (hr) |
IL (1) | IL258213B (hr) |
LT (1) | LT3356350T (hr) |
MA (1) | MA43032A (hr) |
MX (1) | MX2018004008A (hr) |
PH (1) | PH12018500610A1 (hr) |
PL (1) | PL3356350T3 (hr) |
PT (1) | PT3356350T (hr) |
SA (1) | SA518391218B1 (hr) |
SG (1) | SG10201912833XA (hr) |
SI (1) | SI3356350T1 (hr) |
TW (1) | TWI761315B (hr) |
WO (1) | WO2017055860A1 (hr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
US10925880B2 (en) * | 2016-09-23 | 2021-02-23 | Bayer Pharma Aktiengesellschaft | Combination of PI3K-inhibitors |
GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
CN107118183B (zh) * | 2017-05-17 | 2021-02-02 | 成都化润药业有限公司 | 一种四氢-3-呋喃甲醇的合成方法 |
WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
WO2019073399A1 (en) * | 2017-10-11 | 2019-04-18 | Aurigene Discovery Technologies Limited | CRYSTALLINE FORMS OF 1,2,4-OXADIAZOLE SUBSTITUTED IN POSITION 3 |
US11497735B2 (en) | 2017-11-06 | 2022-11-15 | Aurigene Discovery Technologies Limited | Conjoint therapies for immunomodulation |
CN111868088A (zh) * | 2018-03-20 | 2020-10-30 | 诺华股份有限公司 | 药物组合 |
CN110194760B (zh) * | 2019-05-27 | 2021-08-17 | 浙江农林大学暨阳学院 | 制备3-亚苄基-2-(7’-喹啉)-2,3-二氢-异吲哚-1-酮类化合物的方法 |
JP2022534650A (ja) * | 2019-05-31 | 2022-08-03 | 海思科医▲薬▼有限公司 | Btk阻害薬環誘導体、その調製方法及びその医薬品適用 |
GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
JP7508584B2 (ja) * | 2020-04-29 | 2024-07-01 | リレー セラピューティクス, インコーポレイテッド | PI3Kα阻害剤およびそれらの使用 |
CN116194088A (zh) | 2020-08-27 | 2023-05-30 | 大冢制药株式会社 | 使用mdm2拮抗剂治疗癌症的生物标志物 |
GB202103080D0 (en) | 2021-03-04 | 2021-04-21 | Otsuka Pharma Co Ltd | Cancer biomarkers |
CN118302427A (zh) * | 2021-12-02 | 2024-07-05 | 上海翰森生物医药科技有限公司 | 稠环类衍生物调节剂、其制备方法和应用 |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH374071A (de) | 1959-04-30 | 1963-12-31 | Geigy Ag J R | Verfahren zur Herstellung von neuen Isoindolinderivaten |
US3466298A (en) | 1967-03-14 | 1969-09-09 | American Home Prod | Process for the preparation of 2-(2-aminoethyl)isoindolines |
US3763178A (en) | 1968-09-05 | 1973-10-02 | American Home Prod | Imidazolinyl phenyl carbonyl acid addition salts and related compounds |
GB1325065A (en) | 1970-02-12 | 1973-08-01 | American Home Prod | Imidazoline derivatives |
AR203991A1 (es) | 1972-03-16 | 1975-11-12 | Rhone Poulenc Sa | Procedimiento para preparar derivados de(hidroxi-2-amino-3-propoxi)-3-isoindolinona-1 |
FR2217000B1 (hr) | 1973-02-08 | 1976-04-09 | Rhone Poulenc Ind | |
GB1601701A (en) | 1977-07-22 | 1981-11-04 | Delmar Chem | Production of heterocyclic benzamide compounds |
US4200759A (en) | 1978-07-20 | 1980-04-29 | Delmar Chemicals, Limited | Preparation of imidazo[2,1-a]isoindole compounds |
US4244966A (en) | 1979-09-24 | 1981-01-13 | American Home Products Corporation | 1,3-Dihydro-3-(2-hydroxy-, 2-bromo- or 2-chloroethyl)-2H-isoindol-1-one derivatives |
US4312809A (en) | 1980-10-31 | 1982-01-26 | E. R. Squibb & Sons, Inc. | Lactam derivatives of mercaptoacylamino acids |
US4331600A (en) | 1980-10-31 | 1982-05-25 | Usv Pharmaceutical Corporation | Intermediates for the synthesis of phthalimidines |
FR2533563A1 (fr) | 1982-09-23 | 1984-03-30 | Adir | Nouveaux derives de la sulfonyluree, leurs procedes de preparation et les compositions pharmaceutiques les renfermant |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
HU212435B (en) | 1990-06-07 | 1996-06-28 | Sandoz Ag | Herbicidal compositions containing substituted phthalides and heterocyclic phthalides as active ingredient and process for preparation of their active ingredients. |
CA2262403C (en) | 1995-07-31 | 2011-09-20 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
TW448172B (en) | 1996-03-08 | 2001-08-01 | Pharmacia & Upjohn Co Llc | Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation |
DE19807423A1 (de) | 1998-02-21 | 1999-08-26 | Hoechst Marion Roussel De Gmbh | Subustituierte Isoindolone, ihre Herstellung und ihre Verwendung in Arzneimitteln |
DE60024631T2 (de) | 1999-07-26 | 2006-06-14 | Banyu Pharma Co Ltd | Biaryl-harnstoff-derivate |
WO2001032928A2 (en) | 1999-11-05 | 2001-05-10 | Phase-1 Molecular Toxicology | Methods of determining individual hypersensitivity to an agent |
DE10134482A1 (de) | 2001-07-16 | 2003-01-30 | Bayer Ag | Substituierte Isoindole und ihre Verwendung |
JP4477351B2 (ja) | 2001-12-18 | 2010-06-09 | エフ.ホフマン−ラ ロシュ アーゲー | シス−2,4,5−トリフェニル−イミダゾリン類及び腫瘍の処理へのそれらの使用 |
FR2840302B1 (fr) | 2002-06-03 | 2004-07-16 | Aventis Pharma Sa | Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
US7521451B2 (en) | 2002-11-26 | 2009-04-21 | Maruishi Pharmaceutical Co., Ltd. | Isoindoline derivative |
JP2004217591A (ja) | 2003-01-16 | 2004-08-05 | Dai Ichi Seiyaku Co Ltd | シス選択的フルオロシクロプロパン誘導体の製造方法 |
US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
JP2005255660A (ja) | 2004-03-10 | 2005-09-22 | Katsuhiko Tomooka | 多官能基を有するラクタム類とその製法 |
JPWO2005095341A1 (ja) | 2004-03-30 | 2007-08-16 | 協和醗酵工業株式会社 | 含窒素複素環化合物 |
TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
GB0419481D0 (en) | 2004-09-02 | 2004-10-06 | Cancer Rec Tech Ltd | Isoindolin-1-one derivatives |
CA2752738C (en) | 2005-02-22 | 2014-05-27 | The Regents Of The University Of Michigan | Small molecule inhibitors of mdm2 and uses thereof |
US7705021B2 (en) | 2005-05-02 | 2010-04-27 | Fox Chase Cancer Center | Isoindolone compounds, compositions containing the same, and methods of use thereof for the treatment of viral infections related to the etiology of cancer |
WO2007021309A1 (en) | 2005-08-12 | 2007-02-22 | Astrazeneca Ab | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
EP2108642A1 (en) * | 2006-10-17 | 2009-10-14 | Kyowa Hakko Kirin Co., Ltd. | Jak inhibitor |
GB0706072D0 (en) | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
MX2009013169A (es) | 2007-06-03 | 2010-04-30 | Univ Vanderbilt | Moduladores alostericos positivos del mglur5 benzamida y metodos de elaboracion y uso de los mismos. |
US20090156735A1 (en) * | 2007-12-14 | 2009-06-18 | General Electric Company | Composition, article, and associated method |
GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
DE102008031517A1 (de) | 2008-07-03 | 2010-01-07 | Merck Patent Gmbh | Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate |
EP2340021B1 (en) | 2008-09-18 | 2012-11-07 | F. Hoffmann-La Roche AG | Substituted pyrrolidine-2-carboxamides |
US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
FR2944282B1 (fr) * | 2009-04-09 | 2013-05-03 | Sanofi Aventis | Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques |
CA2780547C (en) | 2009-11-12 | 2015-02-03 | The Regents Of The University Of Michigan | Spiro-oxindole mdm2 antagonists |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
SG193002A1 (en) | 2011-03-10 | 2013-09-30 | Daiichi Sankyo Co Ltd | Dispiropyrrolidine derivative |
EP2721007B1 (en) | 2011-06-20 | 2015-04-29 | Novartis AG | Cyclohexyl isoquinolinone compounds |
WO2012175520A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
JO3357B1 (ar) | 2012-01-26 | 2019-03-13 | Novartis Ag | مركبات إيميدازوبيروليدينون |
KR101401705B1 (ko) | 2012-01-31 | 2014-06-27 | 울산대학교 산학협력단 | 로듐 촉매를 이용한 이소인돌린 유도체의 합성방법 |
US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
EP2838898B1 (en) * | 2012-04-20 | 2017-01-18 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
RS60122B1 (sr) | 2012-10-30 | 2020-05-29 | Mei Pharma Inc | Kombinovane terapije za lečenje hemorezistentnih kancera |
BR112015031542A2 (pt) | 2013-07-03 | 2017-07-25 | Hoffmann La Roche | métodos de previsão de reação de pacientes com câncer, método de tratamento de câncer, kit de previsão da reação ao tratamento e processos, métodos e usos inovadores |
EP3094746A1 (en) | 2014-01-14 | 2016-11-23 | Daiichi Sankyo Company, Limited | Gene signatures associated with sensitivity to mdm2 inhibitors |
AU2015247646B2 (en) | 2014-04-17 | 2019-06-06 | The Regents Of The University Of Michigan | MDM2 inhibitors and therapeutic methods using the same |
EP3204514A1 (en) | 2014-10-09 | 2017-08-16 | Daiichi Sankyo Co., Ltd. | Algorithms for gene signature-based predictor of sensitivity to mdm2 inhibitors |
EP3206697A2 (en) | 2014-10-17 | 2017-08-23 | Biomirna Holdings Ltd. | Lung cancer diagnostics and therapeutics with mir-660 |
GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
GB201517217D0 (en) * | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
MA47013A (fr) | 2015-10-21 | 2018-08-29 | Otsuka Pharma Co Ltd | Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase |
TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
US11339448B2 (en) | 2018-07-27 | 2022-05-24 | Ottawa Hospital Research Institute | Treatment of acute myeloid leukemia |
WO2020169073A1 (en) | 2019-02-24 | 2020-08-27 | Ascentage Pharma (Suzhou) Co., Ltd. | Treatment methods and biomarkers for mdm2 inhibitors |
GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
CN116194088A (zh) | 2020-08-27 | 2023-05-30 | 大冢制药株式会社 | 使用mdm2拮抗剂治疗癌症的生物标志物 |
GB202103080D0 (en) | 2021-03-04 | 2021-04-21 | Otsuka Pharma Co Ltd | Cancer biomarkers |
-
2015
- 2015-09-29 GB GBGB1517217.4A patent/GB201517217D0/en not_active Ceased
-
2016
- 2016-09-29 US US15/763,698 patent/US10544132B2/en active Active
- 2016-09-29 FI FIEP16777770.5T patent/FI3356350T3/fi active
- 2016-09-29 SG SG10201912833XA patent/SG10201912833XA/en unknown
- 2016-09-29 ES ES16777770T patent/ES2934181T3/es active Active
- 2016-09-29 PT PT167777705T patent/PT3356350T/pt unknown
- 2016-09-29 TW TW105131385A patent/TWI761315B/zh active
- 2016-09-29 SI SI201631642T patent/SI3356350T1/sl unknown
- 2016-09-29 EP EP16777770.5A patent/EP3356350B1/en active Active
- 2016-09-29 AU AU2016330030A patent/AU2016330030C1/en active Active
- 2016-09-29 EP EP22200147.1A patent/EP4151633A1/en active Pending
- 2016-09-29 JP JP2018515229A patent/JP7029387B2/ja active Active
- 2016-09-29 PL PL16777770.5T patent/PL3356350T3/pl unknown
- 2016-09-29 HR HRP20221487TT patent/HRP20221487T1/hr unknown
- 2016-09-29 WO PCT/GB2016/053042 patent/WO2017055860A1/en active Application Filing
- 2016-09-29 DK DK16777770.5T patent/DK3356350T3/da active
- 2016-09-29 CA CA2999400A patent/CA2999400A1/en active Pending
- 2016-09-29 CN CN201680056529.2A patent/CN108290871B/zh active Active
- 2016-09-29 BR BR112018005932-3A patent/BR112018005932B1/pt active IP Right Grant
- 2016-09-29 LT LTEPPCT/GB2016/053042T patent/LT3356350T/lt unknown
- 2016-09-29 CN CN202211044004.0A patent/CN115572252A/zh active Pending
- 2016-09-29 KR KR1020187008605A patent/KR20180081706A/ko not_active Application Discontinuation
- 2016-09-29 MA MA043032A patent/MA43032A/fr unknown
- 2016-09-29 HU HUE16777770A patent/HUE060638T2/hu unknown
- 2016-09-29 MX MX2018004008A patent/MX2018004008A/es unknown
-
2018
- 2018-03-19 IL IL258213A patent/IL258213B/en unknown
- 2018-03-21 PH PH12018500610A patent/PH12018500610A1/en unknown
- 2018-03-28 SA SA518391218A patent/SA518391218B1/ar unknown
- 2018-08-09 HK HK18110249.8A patent/HK1250715A1/zh unknown
-
2019
- 2019-08-08 US US16/535,931 patent/US10981898B2/en active Active
-
2021
- 2021-02-01 US US17/164,045 patent/US12071429B2/en active Active
- 2021-05-10 AU AU2021202962A patent/AU2021202962C1/en active Active
-
2022
- 2022-02-18 JP JP2022024315A patent/JP2022070998A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20221487T1 (hr) | Izoindolinonski inhibitori međudjelovanja mdm2-p53 s protuumorskom aktivnošću | |
JP2018534253A5 (hr) | ||
JP2018535927A5 (hr) | ||
FI3356344T3 (fi) | Mdm2-p53-vuorovaikutuksen isoindolinoniestäjiä, joilla on syövänvastaista aktiivisuutta | |
HRP20210450T1 (hr) | Biciklički heterociklusni spojevi i njihova uporaba u terapiji | |
ES2621461T3 (es) | Inhibidores de quinasa de pirazolilquinoxalina | |
JP3822494B2 (ja) | チロシンキナーゼ阻害剤 | |
CA3139120A1 (en) | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof | |
HRP20160852T1 (hr) | Biciklični heterociklični spojevi kao inhibitori protein tirozin kinaze | |
JP2014506877A5 (hr) | ||
BR112016010041A2 (pt) | composto, medicamento, e, uso do composto ou sal | |
EA016564B1 (ru) | Бензил- и пиридинилпроизводные в качестве модуляторов пути передачи сигнала hedgehog | |
TW201202221A (en) | Nitrogen containing heteroaryl compounds | |
BG108098A (bg) | 3-(4-амидопирол-2-илметлиден)-2-индолинонови производни като инхибитори на протеин киназа | |
JP2020518554A5 (hr) | ||
JP2019506367A5 (hr) | ||
WO2016064958A1 (en) | Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors | |
JP2012525367A (ja) | イミダゾール誘導体およびサイクリン依存性キナーゼ類のモジュレーターとしてのその使用 | |
BG108622A (bg) | Комбинирана терапия за лечение на рак | |
CZ243093A3 (en) | Benzofuran derivatives, process of their preparation and pharmaceutical preparations in which they are comprised | |
KR20120026612A (ko) | 벤질 치환 트리아진 유도체와 이들의 치료적 용도 | |
WO2010108921A1 (en) | N-aryl-2-(2-arylaminopyrimidin-4-yl)pyrrol-4-carboxamide derivatives as mps1 kinase inhibitors | |
CN100457728C (zh) | 酪氨酸激酶抑制剂 | |
JP2022553832A (ja) | メラノコルチンサブタイプ-2受容体(mc2r)アンタゴニストおよびその使用 | |
JP2003505369A (ja) | 偏頭痛を治療するための複素環式化合物 |